愛齊科技 (ALGN) 2020 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Greetings, and welcome to Align Technology's Third Quarter 2020 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded.

    各位好,歡迎參加愛齊科技(Align Technology)2020 年第三季財報電話會議。(接線員指示)提醒各位,本次會議將被錄音。

  • It is now my pleasure to introduce your host Shirley Stacy, Vice President, Corporate and Investor Communications. Thank you. You may begin.

    現在很榮幸為各位介紹本次會議主持人:企業與投資人溝通副總裁 Shirley Stacy。謝謝。您可以開始了。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Thank you for joining us, everyone. Joining me on today's call is Joe Hogan, President and CEO; and John Morici, CFO. We issued third quarter 2020 financial results today via Globe Newswire, which is available on our website at investor.aligntech.com.

    感謝各位加入我們今天的會議。今天與我一同出席的有總裁暨執行長 Joe Hogan,以及財務長 John Morici。我們已於今日透過 Globe Newswire 發布 2020 年第三季財務結果,您可至 investor.aligntech.com(我們的網站)查閱。

  • Today's conference call is being audio webcast and will be archived on our website for approximately 1 month. A telephone replay will be available today by approximately 5:30 p.m. Eastern Time through 5:30 p.m. Eastern Time on November 4. To access the telephone replay, domestic dialers should dial (877) 660-6853 with conference number 13710706 followed by pound. International callers should dial (201) 612-7415 with the same conference number.

    今天的電話會議將以音訊網路直播,並會在我們網站上保存約 1 個月。電話重播將於今日美東時間約下午 5:30 起提供,並持續至 11 月 4 日美東時間下午 5:30。若要收聽電話重播,美國境內請撥打 (877) 660-6853,輸入會議號碼 13710706 後按井字鍵。國際來電者請撥打 (201) 612-7415,並輸入相同會議號碼。

  • As a reminder, the information provided and discussed today will include forward-looking statements, including statements about Align's future events and product outlook. These forward-looking statements are only predictions and involve risks and uncertainties that are described in more detail in our most recent periodic reports filed with the Securities and Exchange Commission available on our website and at sec.gov. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements.

    提醒各位,今天提供與討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件與產品展望的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容在我們最近期向美國證券交易委員會(SEC)提交的定期報告中有更詳細說明,該等文件可於我們網站及 sec.gov 查閱。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。

  • We have posted historical financial statements, including the corresponding reconciliations, including our GAAP and non-GAAP reconciliation, if applicable. And our third quarter 2020 conference call slides on our website under quarterly results. Please refer to these files for more detailed information.

    我們已在網站上公布歷史財務報表及相對應的調節表(如適用,包括 GAAP 與非 GAAP 的調節),以及 2020 年第三季財報電話會議簡報,位置在「季度業績」專區。請參考這些檔案以取得更詳細資訊。

  • With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?

    接下來,我將把電話交給愛齊科技總裁暨執行長 Joe Hogan。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, Shirley. Good afternoon, and thanks for joining us. I'm pleased to report stronger-than-expected results with record third quarter revenues up 21% year-over-year, reflecting strong momentum across all regions and customer channels for both Invisalign clear aligners and iTero scanners and services.

    謝謝你,Shirley。各位下午好,感謝加入我們。我很高興報告本季表現優於預期:第三季營收創新高,年增 21%,反映 Invisalign 隱形矯正器以及 iTero 掃描儀與服務在所有地區與各客戶通路皆展現強勁動能。

  • During the quarter, we continued to support doctor recovery efforts with products, programs and virtual tools and training that help more docs transition their practices to digital technologies and drove record utilization across the Invisalign portfolio. Capping off a record quarter is an achievement of our ninth million Invisalign patient milestone.

    本季我們持續透過產品、方案以及虛擬工具與訓練,支持醫師的復甦努力,協助更多醫師將診所轉型至數位技術,並推動 Invisalign 產品組合的使用率創下新高。為這個創紀錄的季度畫下句點的是:我們達成第 900 萬名 Invisalign 病患的里程碑。

  • We also saw a strong response to our new teen-and-mom-focused consumer campaign with 118% year-over-year increase in total leads, garnered 3.3 billion impressions, an uptick in consumer engagement from new social media influencers like Charli D' Amelio and Marsai Martin, and 26% increase year-over-year in teenagers using Invisalign clear aligners.

    我們也看到市場對全新「青少年與媽媽」主題消費者行銷活動的強烈回應:總潛在客戶(leads)年增 118%,累積 33 億次曝光;並因 Charli D' Amelio、Marsai Martin 等新社群媒體影響者帶動,消費者互動提升;使用 Invisalign 隱形矯正器的青少年人數亦年增 26%。

  • Our overall revenue momentum has continued into October, and we are encouraged by positive feedback from Invisalign practices regarding the benefits of digital orthodontics, starting with an iTero scanner for Invisalign treatment especially in this COVID environment.

    我們整體營收動能延續至 10 月;同時,我們也受到 Invisalign 診所對數位矯正效益之正面回饋所鼓舞,尤其是在 COVID 環境下,從使用 iTero 掃描儀進行 Invisalign 治療開始。

  • For Q3, total revenues were $733 million, up 108% sequentially and up 21% year-over-year, reflecting a sharp rebound in sales for both Invisalign clear aligners and iTero imaging systems as practices around the world reopened and got back to work treating existing and new patients.

    第三季總營收為 7.33 億美元,季增 108%,年增 21%;反映全球各地診所重新開業並恢復為既有與新病患提供治療後,Invisalign 隱形矯正器與 iTero 影像系統的銷售皆出現強勁反彈。

  • Q3 revenues for clear aligners were $621 million, up 20% year-over-year, and Imaging Systems & and CAD/CAM Services were $113.4 million, up 24.5% year-over-year. Q3 and Invisalign shipments were a record of 496,000 cases, up 28.7% versus prior year and up 124% versus prior quarter, reflecting strong recovery across all regions.

    第三季隱形矯正器營收為 6.21 億美元,年增 20%;影像系統與 CAD/CAM 服務營收為 1.134 億美元,年增 24.5%。第三季 Invisalign 出貨量創紀錄達 49.6 萬例(cases),較去年同期增加 28.7%,較前一季增加 124%,反映各地區皆呈現強勁復甦。

  • During the quarter, we saw increased demand for new cases as restrictions eased and doctors ramped up their practices. This is in contrast to Q2 where doctors' primary focus was to maintain continuity of patient care for their existing patients through additional aligner shipments and replacement aligners. John mentioned this in his comments last quarter and we'll touch on it again today.

    本季隨著限制措施放寬、醫師加速恢復診所營運,我們看到新病例需求增加。這與第二季形成對比:當時醫師的主要重點是透過額外出貨矯正器與替換矯正器,維持既有病患照護的連續性。John 在上季的評論中提到過這點,我們今天也會再談到。

  • For the quarter, we shipped Invisalign cases to a record 70,000 doctors, of which 5,800 were first-time customers, reflecting increased doctor activity as practices have reopened. We have also trained approximately 6,500 new doctors in Q3, including 3,200 international doctors, reflecting increased doctor engagement through our online virtual education courses, summits and forums.

    本季我們向創紀錄的 70,000 位醫師出貨 Invisalign 病例,其中 5,800 位為首次購買客戶,反映診所重新開業後醫師活動增加。我們在第三季也訓練了約 6,500 位新醫師,其中包含 3,200 位國際醫師,顯示透過線上虛擬教育課程、峰會與論壇,醫師參與度提升。

  • Across the business, we believe there are several factors contributing to our strong performance, starting with pent-up demand. Many of our doctors indicate that they are making good progress in working the backlog of patients from office shutdowns. Pent-up disposable income remains a key factor as consumers focus on feel-good investments, while many other quality of life options are low.

    就整體業務而言,我們認為有數項因素促成了強勁表現,首先是被壓抑的需求。許多醫師表示,他們在處理因診所停業而累積的病患待辦量方面進展良好。被壓抑的可支配所得仍是關鍵因素,因為消費者更聚焦於能帶來愉悅感的投資,而其他許多生活品質選項仍然有限。

  • In our new normal, there are far fewer trips abroad, fewer flights, less money spent on gas, dry cleaning, et cetera. More people can afford to allocate that spending to Invisalign treatment, especially when they're working remotely and critiquing themselves on camera, so much of the time. That's the Zoom effect we've heard about across multiple sectors.

    在新的常態下,出國旅行大幅減少、航班更少、汽油費支出降低、乾洗等開銷也減少。更多人能把這些支出轉而投入 Invisalign 治療,尤其在遠端工作、經常在鏡頭前檢視自己時更是如此。這就是我們在多個產業都聽到的「Zoom 效應」。

  • As we look at our customer channels, we feel the strategy to dedicate sales representatives by specialty alignment is bearing fruit, particularly in the GP dental segment. Sales reps were able to partner with a wider range of providers within their designated specialty during the downturn and assess mindset and specific needs during the recovery and tailor plans to thrive beyond COVID.

    從客戶通路來看,我們認為依專科對齊配置專屬業務代表的策略正在開花結果,尤其是在一般牙科(GP)領域。在景氣下行期間,業務代表能與其所負責專科內更廣泛的服務提供者合作,評估其心態與復甦期的特定需求,並量身打造計畫,以在 COVID 之後持續成長。

  • A digital mindset has been key, and we believe this is the largest influence in the ortho market and the one we've been laying the foundation for over the last several years. For many doctors, they are still down from normal years in terms of overall production and weekly patient flow. But they have prioritized Invisalign clear aligners as their preferred modality expanded to the first age group and leverage programs that help to make the transition from analog to digital treatment. We see this both in teen and adult treatment growing with the same provider, increased use of iTero scanners, our virtual care, our high overlap of bracket buyback switch.

    數位思維一直是關鍵;我們相信這是矯正市場中影響最大的一股力量,也是我們過去數年持續奠基的方向。對許多醫師而言,就整體產能與每週病患流量來說仍低於正常年度水準;但他們已將 Invisalign 隱形矯正器列為首選治療方式,並擴展至更早的年齡族群,同時運用各項方案協助從類比治療轉向數位治療。我們在多方面都看到這點:同一位提供者的青少年與成人治療同步成長、iTero 掃描儀使用增加、我們的虛擬照護、以及托槽回購轉換(bracket buyback switch)的高重疊度。

  • As part of our recovery programs, we offer doctors 2 programs, either switch their braces in patients into Invisalign treatment by buying their wires and brackets or just buy back their existing inventory. We took out the equivalent of 10,000 cases. Providers actively reduced their analog footprints by proactively switching their patients to sustainable digital care with Invisalign. And for GPs who already demonstrated momentum with digital, an active choice was made to position Invisalign as a priority. Scanning every patient with iTero is generating more opportunity from recall patients even if overall practice capacity is still down. Because doctors in both channels are trying to anticipate what may come in terms of additional waves and office shutdowns, they are hyper-focused on ensuring that they have the best plan for continuity of care and business continuity, which is digital.

    作為我們復甦方案的一部分,我們為醫師提供兩種方案:其一是透過回購鋼絲與托槽,將配戴牙套的病患轉換為 Invisalign 治療;其二是僅回購其既有庫存。我們回收了相當於 10,000 例(cases)的量。服務提供者透過主動將病患轉換至以 Invisalign 為核心、可持續的數位照護,積極降低其類比治療的比重。對於已展現數位動能的 GP 而言,也做出了將 Invisalign 定位為優先項目的積極選擇。即使整體診所產能仍偏低,使用 iTero 為每位病患掃描,仍能從回診病患中創造更多機會。由於兩個通路的醫師都在預判可能出現的額外疫情波次與診所再度停業,他們高度聚焦於確保擁有最佳的照護連續性與營運持續性方案,而這就是數位化。

  • To support them in this digital journey, we've rolled out My Invisalign app in virtual care to 40-plus countries. These tools have been received very positively by our doctors and are quickly becoming part of their practice workflow.

    為支持他們的數位旅程,我們已在 40 多個國家推出 My Invisalign 應用程式與虛擬照護。這些工具獲得醫師非常正面的回饋,並迅速成為其診所工作流程的一部分。

  • Our commitment to continuous innovation is key. We've recently announced our treatment planning evolution and global availability of our next-generation ClinCheck Pro 6.0 proprietary treatment planning software. ClinCheck Pro 6.0 moves Invisalign digital treatment planning to the cloud, making its robust treatment planning tools and features available to doctors anytime, anywhere, on any laptop, personal computer, tablet or phone. The release includes a new ClinCheck in-face visualization tool, an enhanced doctor facing digital clinical tool that combines a photo of their patients face with their 3D Invisalign treatment plan, creating a personalized view of how their new smile will look.

    我們對持續創新的承諾至關重要。我們近期宣布治療規劃的演進,以及新一代專有治療規劃軟體 ClinCheck Pro 6.0 的全球供應。ClinCheck Pro 6.0 將 Invisalign 數位治療規劃移至雲端,使其強大的治療規劃工具與功能可讓醫師隨時隨地、透過任何筆電、個人電腦、平板或手機使用。本次發布包含全新的 ClinCheck「臉部視覺化」(in-face visualization)工具:這是一項強化的醫師端數位臨床工具,將病患臉部照片與其 3D Invisalign 治療計畫結合,呈現個人化視圖,讓病患能看到新笑容的樣貌。

  • In addition, we also announced today Invisalign G8 predictability improvement with SmartForce Aligner Activation for both orthodontists and general dentists starting in Q1 2021. The Invisalign G8 with SmartForce Aligner Activation is our newest biomechanical innovation and the latest in our long history of Invisalign predictability improvements.

    此外,我們今天也宣布將於 2021 年第一季起,針對矯正專科醫師與一般牙醫推出 Invisalign G8 的可預測性提升:搭載 SmartForce Aligner Activation。Invisalign G8 搭配 SmartForce Aligner Activation 是我們最新的生物力學創新,也是我們長期以來持續提升 Invisalign 可預測性歷程中的最新成果。

  • We continue to focus on building partnership with doctors. Our data shows the providers who have or quickly developed momentum around digital orthodontics, leaned into our comprehensive platform in a variety of our programs and resources to accelerate a digital shift. It's a compelling story of how engagement may be the first step, but transformation is achieved through the breadth of product and services only Align can provide.

    我們持續專注於與醫師建立夥伴關係。我們的數據顯示,那些已經或迅速在數位矯正領域建立動能的醫療提供者,會透過我們多元的方案與資源,更深入採用我們的全方位平台,以加速數位轉型。這是一個很有說服力的故事:互動參與或許是第一步,但真正的轉型是透過只有 Align 能提供的廣泛產品與服務來實現。

  • Transformation and support programs like ADAPT, virtual tools, development of teen awesomeness centers, GP accelerator, teen conversion, aligner intensive fellowship, iPro and doctor-led coaching programs that support GP growth. Building on the teen market in Q3, 163,000 teens and preteens started treatment with Invisalign clear aligners, representing 33% of total cases shipped, reflecting growth predominantly from North American orthos and EMEA regions.

    轉型與支援方案包括 ADAPT、虛擬工具、青少年卓越中心的建置、GP 加速器、青少年轉換、隱形矯正密集研修(aligner intensive fellowship)、iPro 以及由醫師主導的教練計畫,以支持 GP 成長。延續第三季在青少年市場的動能,共有 163,000 名青少年與學齡前後(preteens)開始使用 Invisalign 隱形牙套治療,占總出貨病例的 33%,成長主要來自北美矯正專科醫師與 EMEA 地區。

  • In parts of the market, we saw an initial rush for teen treatments earlier in the quarter with a slight change in demand profile compared to what we normally see in a typical season, which may be the result of a different type of back-to-school season as most kids return to school late or through virtual learning. Invisalign First continues to accelerate among young patients as well.

    在部分市場,我們看到本季初青少年治療需求出現一波搶先潮,需求型態相較於典型季節略有變化;這可能是因為今年的返校季不同,多數孩子較晚返校或採線上學習。Invisalign First 在年幼患者族群中的成長也持續加速。

  • In terms of product performance, we saw strong growth across the portfolio and noncomprehensive outpace comprehensive, even with the record adult shipments for the quarter. Growth of the Invisalign Go product also increased among GPs driven by North America and EMEA, and there was an increase in our Express package shipments with North America contributing to the majority of that growth. Overall, both noncomprehensive and comprehensive shipments were up, with continued increased adoption of our Moderate product among the ortho and GP channels.

    就產品表現而言,我們看到整體產品組合皆有強勁成長,且非全方位(noncomprehensive)產品的成長速度超越全方位(comprehensive),即便本季成人出貨量創下新高亦然。Invisalign Go 產品在 GP 族群中的成長也有所提升,主要由北美與 EMEA 帶動;同時,我們的 Express 套裝出貨量增加,其中大部分成長由北美貢獻。整體而言,非全方位與全方位出貨量皆上升,且矯正專科與 GP 通路對 Moderate 產品的採用持續提高。

  • Now let's turn to the specifics around our third quarter results, starting with the Americas. For the Americas region, Q3 Invisalign case volume was up 166% sequentially and 25% year-over-year, reflecting an increase in shipments due in large part to the digital programs and tools implemented during the pandemic to help our doctors as well as our continued investments in targeted marketing and sales efforts.

    接下來我們聚焦第三季業績細節,先從美洲開始。美洲地區第三季 Invisalign 病例量較前一季成長 166%,較去年同期成長 25%,反映出貨量增加,主要得益於疫情期間導入的數位方案與工具以協助醫師,以及我們持續在精準行銷與銷售投入上的努力。

  • The Q3 utilization was up for North American orthos and GPs both quarter-over-quarter and year-over-year. We saw a continued utilization increases during the quarter, especially among our orthodontic customers in the teen segment, the strongest teen quarter in the last 6 quarters. As we mentioned previously, in Q2, we started a bracket buyback program to enable doctors to switch their braces patients into Invisalign treatment by buying back their wires and brackets inventory.

    第三季北美矯正專科醫師與 GP 的使用率(utilization)不論季比或年比皆上升。本季使用率持續提高,尤其是在青少年族群的矯正客戶中表現突出,為過去 6 個季度中最強的青少年季度。如先前所述,我們在第二季啟動托槽回購(bracket buyback)計畫,透過回購醫師的鋼絲與托槽庫存,讓醫師能將原本使用傳統牙套的患者轉換為 Invisalign 治療。

  • We also saw stronger growth in the adult segment. We believe that some of the increase in adult shipments is reflective of how circumstances have changed today, with adults in our target demographic having more disposable, direct -- more disposable income directed at getting their smiles fixed.

    我們也看到成人族群成長更為強勁。我們認為成人出貨量增加的一部分,反映了當前環境的變化:目標族群的成人擁有更多可支配資金——且更多可支配所得被用於改善笑容。

  • In Latin America, volume was also up year-over-year, led by strong growth in Mexico and Brazil. When you consider the timing of the pandemic and the shutdowns occurring later in Q2 for Lat Am, we were encouraged by the growth this quarter. We also saw increased utilization in the GP channel with Invisalign Go and adoption of Moderate. DSO utilization also increased and continues to be strong growth driven by Heartland and also Aspen.

    在拉丁美洲,病例量亦較去年同期成長,主要由墨西哥與巴西的強勁成長帶動。考量拉美地區疫情時點以及第二季後段才發生的停業措施,我們對本季的成長感到鼓舞。我們也看到 GP 通路在 Invisalign Go 的使用率提升,並採用 Moderate。DSO 的使用率也提高,且在 Heartland 與 Aspen 的帶動下持續強勁成長。

  • For our international business, Q3 Invisalign case volume was up a sequential 88%, led by a significant increase in EMEA. On a year-over-year basis, international shipments were up 34%, reflecting increases through both EMEA and APAC.

    在國際業務方面,第三季 Invisalign 病例量較前一季成長 88%,主要由 EMEA 的顯著增加帶動。以年比來看,國際出貨量成長 34%,反映 EMEA 與 APAC 皆有增加。

  • For EMEA, Q3 volumes were up sequentially 104% and up 38% on a year-over-year basis across all markets with strong performances from the ortho channel as well as the GP channel as many doctors kept their offices open during their typical summer holiday season. Both core and expansion markets accelerated, with growth in our core markets, led by Iberia, the U.K., Germany and growth in our expansion markets led by Central and Eastern Europe and the Benelux.

    在 EMEA,第三季病例量季比成長 104%,年比成長 38%,所有市場皆有成長;矯正專科通路與 GP 通路表現強勁,因為許多醫師在其典型暑期假期期間仍維持診所營運。核心市場與擴張市場皆加速成長;核心市場的成長由伊比利亞、英國、德國領先,擴張市場的成長則由中東歐與比荷盧(Benelux)領先。

  • We introduced the Ortho Recovery 360 Program in EMEA last quarter to support our orthodontists as they started reopening their businesses. As of Q3, over 4,000 orthodontists have enrolled in the program, with over 13,000 touch points with sales team members providing a dedicated support in July and August alone. As a result, we continue to see an increase in Net Promoter Score, or NPS, with qualitative feedback from doctors showing that they appreciate Align for the support during this difficult time.

    我們在 EMEA 於上一季推出 Ortho Recovery 360 計畫,以支援矯正專科醫師在重新開業時的需求。截至第三季,已有超過 4,000 名矯正專科醫師加入該計畫,僅 7 月與 8 月就有超過 13,000 次與銷售團隊成員的接觸點,提供專屬支援。因此,我們持續看到淨推薦值(Net Promoter Score,NPS)提升;醫師的質性回饋顯示,他們感謝 Align 在這段艱難時期所提供的支持。

  • We also rolled out your billing -- Your Brilliance Enhanced marketing campaign to selected EMEA markets that highlights the skills of our orthodontists and illustrates how partnering with Align in using Invisalign clear aligners and iTero systems and services can help further enhance the brilliance of these specialists.

    我們也在部分 EMEA 市場推出「Your Brilliance Enhanced」行銷活動,強調矯正專科醫師的專業技能,並展示與 Align 合作、使用 Invisalign 隱形牙套以及 iTero 系統與服務,如何進一步提升這些專家的卓越表現。

  • To support our GP doctors, we also launched our GP Recovery 360 program during the quarter with over 2,900 GPs enrolled so far. At the beginning of the quarter, we also launched an Invisalign Go Plus system in the U.K. and Benelux and had 2,500 GPs attend the event. During the quarter, we continue to offer virtual and hybrid education events for our doctors with online and on-demand education events, which reached over 2,000 GPs cumulatively.

    為了支援 GP 醫師,我們也在本季推出 GP Recovery 360 計畫,目前已有超過 2,900 名 GP 加入。本季初,我們也在英國與比荷盧推出 Invisalign Go Plus 系統,並有 2,500 名 GP 參與活動。本季期間,我們持續為醫師提供線上與混合式教育活動,包括線上與隨選(on-demand)課程,累計觸及超過 2,000 名 GP。

  • For APAC, in Q3, volumes were up sequentially, 74%, reflecting continued improvement within the region. On a year-over-year basis, APAC was up 30% compared to the prior year.

    在 APAC,第三季病例量較前一季成長 74%,反映區域內持續改善。以年比來看,APAC 較去年成長 30%。

  • During the quarter, we're pleased to see a record number of unique doctors submitting cases and positive growth in the adult segment with growth in GP channels and noncomprehensive cases with Moderate product. In the teen segment, shipments were at an all-time high as doctors' offices continue to recover. We also saw acceleration from Japan and ANZ.

    本季我們很高興看到提交病例的獨立醫師數量創下新高,成人族群也呈現正成長,成長來自 GP 通路以及採用 Moderate 產品的非全方位病例。在青少年族群方面,隨著診所持續復甦,出貨量創歷史新高。我們也看到日本與澳紐(ANZ)加速成長。

  • During the quarter, we celebrated the grand opening of our China manufacturing facility in Ziyang. The event was attended by key partners and doctors in China. The state of the art facility replaces our original temporary facility, further establishing our commitment and capacity to manufacture Invisalign aligners and iTero imaging systems in China.

    本季期間,我們慶祝位於資陽的中國製造工廠盛大開幕,活動由中國的重要合作夥伴與醫師出席。這座最先進的設施取代了我們原先的臨時工廠,進一步展現我們在中國製造 Invisalign 隱形牙套與 iTero 影像系統的承諾與產能。

  • Align was also one of the sponsors of APACMed Virtual Forum 2020, which attracted over 1,000 attendees from the medtech industry. The forum consisted of panel discussions in live video chat sessions at the Align virtual booth as we continue to establish Align as a global medical company that aims to transform smiles and change lives in the APAC region.

    Align 也是 APACMed Virtual Forum 2020 的贊助商之一,該論壇吸引了超過 1,000 名醫療科技產業與會者。論壇包含在 Align 虛擬攤位進行的即時視訊聊天座談討論;我們持續將 Align 建立為全球醫療公司,致力於在 APAC 地區改變笑容、改變人生。

  • Last week, we also hosted the Align APAC Virtual Symposium, a fully digital event that showcased a digital treatment technologies and featured practitioners from across the Asia Pacific region with over 800 participants. Our consumer marketing is focused on building the clear aligner category and driving demand for Invisalign treatment through a doctor's office.

    上週,我們也舉辦 Align APAC Virtual Symposium,這是一場全數位活動,展示數位治療技術,並邀請亞太地區各地的臨床從業者參與,吸引超過 800 名參與者。我們的消費者行銷聚焦於建立隱形牙套品類,並透過醫師診所推動 Invisalign 治療需求。

  • In Q3, we saw strong digital engagement globally with more than 78% increase in unique visitors as well as on leads traded driven by our new campaign, revamped social media strategy and our new invisalign.com website that was rolled out to 15-plus countries. Several key metrics show increased activity engagement with the Invisalign brand and are included in our Q3 quarterly presentation slides available on our website. We're pleased with the strong engagement and activity we've seen on our consumer platforms over the last few months and believe it speaks to the strength of the brand and consumer interest in treatment even during the challenges of the last few months.

    在第三季,我們看到全球數位互動表現強勁,獨立訪客數增加超過 78%,以及由新活動、重新調整的社群媒體策略與新版 invisalign.com 網站(已在 15 個以上國家上線)所帶動的線索(leads)也增加。多項關鍵指標顯示 Invisalign 品牌的互動與活躍度提升,並已納入我們網站上可取得的第三季簡報投影片。我們對過去幾個月在消費者平台上看到的強勁互動與活動感到滿意,並認為這反映品牌實力,以及即使在近幾個月的挑戰之下,消費者對治療仍具高度興趣。

  • As you recall from last quarter, we launched our Mom multitouch campaign with incremental support to drive reach, awareness and foot traffic to practices during the key teen season. We also launched a new multimillion-dollar TV campaign designed to reach mom and teens across a broad range of networks nationwide, including cable and connected TV networks.

    如同各位記得的,我們在上一季推出 Mom 多觸點(multitouch)行銷活動,並加碼支援以在青少年旺季期間提升觸及、認知與到診所的來客量。我們也推出一項新的數百萬美元電視廣告活動,旨在透過全國多元的電視頻道觸及媽媽與青少年,包括有線電視與連網電視(connected TV)網路。

  • Align is always looking for new opportunities to reach consumers and be relevant to potential patients wherever they work, live and play.

    Align 一直在尋找新的機會觸及消費者,並在潛在患者工作、生活與休閒的各個場景中保持相關性。

  • During the quarter, we announced that the Invisalign brand is the official clear aligner sponsor of the NFL Football League. With 11 NFL teams working with great sports brands like the NFL is another way to connect with consumers by leveraging the power of the NFL brand in its existing brand platforms. The NFL League partnership will help build awareness of Invisalign clear aligner treatment at a national level, while the team agreement will help us engage with key markets and connect consumers with doctors in those markets.

    本季期間,我們宣布 Invisalign 品牌成為 NFL 美國國家美式足球聯盟的官方隱形牙套贊助商。與 NFL 這樣的頂尖運動品牌合作,且有 11 支 NFL 球隊參與,是另一種透過運用 NFL 品牌在其既有品牌平台上的影響力來連結消費者的方式。與 NFL 聯盟的合作將有助於在全國層級提升 Invisalign 隱形牙套治療的知名度,而與球隊的協議將協助我們在關鍵市場深化互動,並將消費者與這些市場中的醫師連結起來。

  • During the quarter, we also extended our innovation to drive engagement with new Invisalign Stickables designed to personalize Invisalign clear aligners, especially for younger patients. The innovative sticker accessories designed exclusively for use with SmartTrack material are available in a variety of designs, colors, shapes and themes and reflect patients' desire to show their personal flair during Invisalign treatment.

    在本季度,我們也延伸創新以提升互動度,推出全新 Invisalign Stickables,旨在為 Invisalign 隱形矯正器提供個人化設計,特別是針對較年輕的患者。這些專為 SmartTrack 材料設計的創新貼紙配件,提供多種設計、顏色、形狀與主題選擇,反映患者在 Invisalign 治療期間展現個人風格的需求。

  • For our Systems and Services business, Q3 revenues were up 110% sequentially due to higher shipments and service revenues. We continue to see momentum with Element 5D imaging system, gaining traction in North America and APAC region.

    就我們的系統與服務(Systems and Services)業務而言,第三季營收較前一季成長 110%,主要因出貨量與服務營收增加。我們持續看到 Element 5D 影像系統的動能,在北美與亞太(APAC)地區逐步獲得市場採用。

  • On a year-over-year basis, System and Services revenues were up 24.5% due to higher shipments and service. Cumulatively, over 27.4 million orthodontic scans and 6 million restorative scans have been performed with iTero scanners.

    以年對年來看,系統與服務營收成長 24.5%,主要受惠於出貨量與服務增加。累計而言,使用 iTero 掃描儀已完成超過 2,740 萬次矯正掃描與 600 萬次修復掃描。

  • For Q3, total Invisalign cases submitted with a digital scanner in the Americas increased to 83% from 79% in Q3 last year. International scans increased to 72%, up from 63% in the same quarter last year. We're pleased to see that within the Americas, 95% of cases submitted by North American orthodontists were submitted digitally.

    第三季,美洲地區使用數位掃描儀提交的 Invisalign 病例占比由去年第三季的 79% 提升至 83%。國際市場的掃描占比提升至 72%,高於去年同季的 63%。我們也很高興看到,在美洲地區中,北美矯正醫師提交的病例有 95% 以數位方式提交。

  • Our Q3 Systems and Services revenue also includes exocad CAD/CAM products and services. exocad's expertise in restorative dentistry, implantology, guided surgery and smile design extends our digital dental solutions and broadens Align's digital platform toward a fully integrated interdisciplinary end-to-end workflows, and we're excited about our continued integration progress and product plans.

    我們第三季的系統與服務營收亦包含 exocad 的 CAD/CAM 產品與服務。exocad 在修復牙科、植牙學、導引手術與微笑設計方面的專業,擴展了我們的數位牙科解決方案,並使 Align 的數位平台朝向完全整合、跨專科端到端工作流程的方向拓展;我們對持續的整合進展與產品規劃感到振奮。

  • In September, exocad celebrated its tenth anniversary in conjunction with exocad Insights 2020, an annual event for manufacturers and users of dental CAD/CAM technologies entitled, A Decade of Digital Innovation. The event attracted over 300 dental technicians, dentists and over 40 partner companies as well as 1,600 users of digital technologies and laboratories and practices from 55 countries.

    9 月,exocad 結合 exocad Insights 2020(面向牙科 CAD/CAM 技術製造商與使用者的年度活動)慶祝成立十週年,活動主題為「A Decade of Digital Innovation(數位創新十年)」。該活動吸引了超過 300 位牙體技術師與牙醫、40 多家合作夥伴公司,以及來自 55 個國家的 1,600 名數位技術使用者與實驗室及診所參與。

  • With that, I'll turn the call over to John.

    接下來,我把電話會議交給 John。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Thanks, Joe. Now for our Q3 financial results. Total revenues for the third quarter were $734.1 million, up 108.4% from the prior quarter and up 20.9% from the corresponding quarter a year ago. For clear aligners, Q3 revenues of $620.8 million were up 108.1% sequentially and up 20.2% year-over-year due to Invisalign volume growth in all regions driven by North America, EMEA, APAC and Lat Am partially offset by lower ASPs.

    謝謝,Joe。接著說明我們第三季的財務結果。第三季總營收為 7.341 億美元,較前一季成長 108.4%,較去年同期成長 20.9%。就隱形矯正器而言,第三季營收為 6.208 億美元,較前一季成長 108.1%,較去年同期成長 20.2%,主要因北美、EMEA、APAC 與拉丁美洲(Lat Am)各地區 Invisalign 量成長所帶動,但部分被較低的平均售價(ASP)所抵銷。

  • Historically, we have raised prices by approximately $50 per case in the third quarter. Given our continued commitment to helping our customers in their recovery efforts, we did not implement a price increase this year.

    過往我們通常會在第三季每個病例調漲約 50 美元。鑑於我們持續致力於協助客戶復甦,我們今年未實施漲價。

  • Q3 Invisalign ASPs were down sequentially $75 primarily due to higher mix of new cases versus additional aligner shipments, as Joe mentioned earlier. Recall, Q2 ASPs benefited from more additional aligner shipments as doctors were focused on maintaining treatment progress for existing Invisalign patients. This trend reversed itself after practices reopened in Q3 and demand for new cases ramped up significantly. As a result, our deferred revenue balance increased $93 million from Q2, of which the majority of this increase is related to clear aligner and will be recognized with future additional aligner shipments.

    第三季 Invisalign 平均售價(ASP)較前一季下降 75 美元,主要因新病例占比提高,相較於追加矯正器出貨的占比下降,如 Joe 先前所提。回顧第二季,因醫師專注於維持既有 Invisalign 患者的治療進度,追加矯正器出貨較多,使 ASP 受惠。診所於第三季重新開放後,此趨勢反轉,新病例需求顯著回升。因此,我們的遞延營收餘額較第二季增加 9,300 萬美元,其中大部分增幅與隱形矯正器相關,並將於未來追加矯正器出貨時認列。

  • On a year-over-year basis, Q3 Invisalign ASPs decreased approximately $80 primarily reflecting higher promotional discounts and increased deferrals related to additional aligners. In addition, we provided doctors with incentives designed to specifically aid them in the recovery during the pandemic.

    以年對年來看,第三季 Invisalign ASP 約下降 80 美元,主要反映較高的促銷折扣,以及與追加矯正器相關的遞延增加。此外,我們也向醫師提供了專門設計的激勵措施,以協助其在疫情期間復甦。

  • Q3 total Invisalign shipments of 496,100 cases were up 123.6% sequentially and up 28.7% year-over-year. Our System and Services revenues for the third quarter was $113.4 million, up 110.1% sequentially due to an increase in scanner sales and increased services revenue from higher installed base.

    第三季 Invisalign 總出貨量為 496,100 例,較前一季成長 123.6%,較去年同期成長 28.7%。第三季系統與服務營收為 1.134 億美元,較前一季成長 110.1%,主要因掃描儀銷售增加,以及裝機基數擴大帶動服務營收提升。

  • Year-over-year Systems and Services revenue was up 24.5% due to higher scanner sales services revenue and the inclusion of exocad's CAD/CAM services partially offset by lower scanner ASPs.

    以年對年來看,系統與服務營收成長 24.5%,主要因掃描儀銷售與服務營收增加,以及納入 exocad 的 CAD/CAM 服務;但部分被較低的掃描儀 ASP 所抵銷。

  • Imaging Systems & CAD/CAM Services deferred revenue also increased 28% primarily due to the increase in scanner sales and the deferral of service revenues, which we recognize ratably over the service period.

    影像系統與 CAD/CAM 服務的遞延營收亦增加 28%,主要因掃描儀銷售增加,以及服務營收的遞延;我們會在服務期間按比例認列該等服務營收。

  • Moving on to gross margin. Third quarter overall gross margin was 72.7%, up 9.1 points sequentially and up 0.7 points year-over-year. On a non-GAAP basis, excluding stock-based compensation expense and amortization of intangibles related to exocad, overall gross margin was 73.3% for the third quarter, up 8.9 points sequentially and up 1 point year-over-year.

    接著看毛利率。第三季整體毛利率為 72.7%,較前一季提升 9.1 個百分點,較去年同期提升 0.7 個百分點。以非 GAAP 基礎計算,排除股份基礎給付費用及與 exocad 相關的無形資產攤銷後,第三季整體毛利率為 73.3%,較前一季提升 8.9 個百分點,較去年同期提升 1 個百分點。

  • Clear aligner gross margin for the third quarter was 74.7%, up 10.2 points sequentially due to increased volumes driving favorable manufacturing absorption of fixed costs, coupled with lower freight costs from increased domestic shipments partially offset by lower ASPs. Clear aligner gross margin was up 1.2 points year-over-year due to increased manufacturing volumes, driving favorable absorption and lower doctor training partially offset by lower ASPs.

    第三季隱形矯正器毛利率為 74.7%,較前一季提升 10.2 個百分點,主要因出貨量增加帶動固定成本吸收改善,加上國內出貨增加使運費成本下降,但部分被較低的 ASP 所抵銷。隱形矯正器毛利率較去年同期提升 1.2 個百分點,主要因製造量增加帶動吸收改善,以及醫師培訓成本下降,但部分被較低的 ASP 所抵銷。

  • Systems and Services gross margin for the third quarter was 62%, up 2.8 points sequentially primarily due to favorable product mix to higher-margin scanners, higher services revenue partially offset by freight and training costs. Systems and Services gross margin was down 2.1 points year-over-year due to lower ASPs and higher freight and training costs offset by higher services revenue and product mix shift.

    第三季系統與服務毛利率為 62%,較前一季提升 2.8 個百分點,主要因產品組合有利(高毛利掃描儀占比提高)及服務營收增加,但部分被運費與培訓成本所抵銷。系統與服務毛利率較去年同期下降 2.1 個百分點,主要因 ASP 較低以及運費與培訓成本較高,但部分被服務營收增加與產品組合轉變所抵銷。

  • Q3 operating expenses were $357 million, up sequentially 20.1% and up 15% year-over-year. The sequential increase in operating expense is due to increased compensation, marketing and media spend and favorable foreign exchange. Year-over-year operating expenses increased by $46.6 million, reflecting our continued investment in sales and marketing and R&D activities. Additionally, prior year included a benefit of $6.8 million from the early termination of our discontinued Invisalign store leases.

    第三季營業費用為 3.57 億美元,較前一季增加 20.1%,較去年同期增加 15%。營業費用的季增主要因薪酬、行銷與媒體支出增加,以及有利的外匯影響。年對年營業費用增加 4,660 萬美元,反映我們持續投資於銷售與行銷以及研發活動。此外,去年同期包含因提前終止已停業的 Invisalign 門市租約而帶來的 680 萬美元收益。

  • On a non-GAAP basis, operating expenses were $332.1 million, up sequentially 25% and up 12.8% year-over-year due to the reasons as described above. Our third quarter operating income of $177.1 million resulted in an operating margin of 24.1%, up 44.8 points sequentially and up 3.2 points year-over-year. The sequential increase in operating income and operating margin are primarily attributed to higher gross margin and operating leverage. On a year-over-year basis, the increases in operating income and operating margin reflect higher gross margin and operating leverage partially offset by our continued investment in R&D, geographic expansion and go-to-market activities.

    以非 GAAP 基礎計算,營業費用為 3.321 億美元,較前一季增加 25%,較去年同期增加 12.8%,原因如上所述。第三季營業利益為 1.771 億美元,營業利益率為 24.1%,較前一季提升 44.8 個百分點,較去年同期提升 3.2 個百分點。營業利益與營業利益率的季增主要歸因於較高的毛利率與營運槓桿。以年對年來看,營業利益與營業利益率的提升反映較高的毛利率與營運槓桿,但部分被我們持續投資於研發、地理擴張與市場推進(go-to-market)活動所抵銷。

  • On a non-GAAP basis, which excludes stock-based compensation, acquisition-related costs and amortization of intangibles related to exocad, operating margin for the third quarter was 28%, up 39 points sequentially and up 4.2 points year-over-year.

    以非 GAAP 基礎計算(排除股份基礎給付、併購相關成本及與 exocad 相關的無形資產攤銷),第三季營業利益率為 28%,較前一季提升 39 個百分點,較去年同期提升 4.2 個百分點。

  • Interest and other income expense net for the third quarter was a gain of $7.5 million primarily driven by favorable foreign exchange. With regards to the third quarter tax provision, our GAAP tax rate was 24.5%, which includes tax benefits of approximately $8 million related to the release of certain previously unrecognized tax benefits as a result of the closure of an income tax audit.

    第三季利息及其他損益淨額為收益 750 萬美元,主要由有利的外匯所帶動。就第三季所得稅費用而言,我們的 GAAP 有效稅率為 24.5%,其中包含約 800 萬美元的稅務利益,係因所得稅稽核結案而釋放部分先前未認列的稅務利益所致。

  • The third quarter tax rate on a non-GAAP basis was 16.6% compared to 27.8% in the prior quarter and 18.8% in the same quarter a year ago. The third quarter non-GAAP tax rate was lower than the second quarter's rate primarily due to reduction in tax benefits resulting from considerable profits recorded in Q3 as opposed to losses incurred in Q2.

    第三季非 GAAP 有效稅率為 16.6%,相較前一季為 27.8%,去年同季為 18.8%。第三季非 GAAP 稅率低於第二季,主要因第三季錄得可觀獲利、相較第二季發生虧損,導致稅務利益減少。

  • Third quarter net income per diluted share was $1.76, up $2.28 sequentially and up $0.48 compared to prior year. On a non-GAAP basis, net income per diluted share was $2.25 for the third quarter, up $2.60 sequentially and up $0.77 year-over-year.

    第三季稀釋後每股淨利為 1.76 美元,較前一季增加 2.28 美元,較去年同期增加 0.48 美元。以非 GAAP 基礎計算,第三季稀釋後每股淨利為 2.25 美元,較前一季增加 2.60 美元,較去年同期增加 0.77 美元。

  • Moving on to the balance sheet. As of September 30, 2020, cash and cash equivalents were $615.5 million, an increase of approximately $211 million from the prior quarter, which is primarily due to higher cash flow from operations. Of our $615.5 million of cash and cash equivalents, $298.8 million was held in the U.S. and $316.7 million was held by our international entities. Q3 accounts receivable balance was $626 million, up approximately 32.3% sequentially.

    接下來談資產負債表。截至2020年9月30日,現金及約當現金為6.155億美元,較前一季增加約2.11億美元,主要係因營運活動帶來較高的現金流量所致。在我們6.155億美元的現金及約當現金中,2.988億美元存放於美國,3.167億美元由我們的國際實體持有。第三季應收帳款餘額為6.26億美元,較前一季約增加32.3%。

  • Our overall days sales outstanding was 76.5 days, down 44 days sequentially and down 2 days as compared to Q3 last year due to strong cash collections as doctors' offices reopened from Q2 shutdowns.

    我們整體應收帳款週轉天數(DSO)為76.5天,較前一季下降44天,較去年第三季下降2天,係因醫師診所自第二季停業後重新開放,帶動強勁的現金回收。

  • Cash flow from operations for the third quarter was $211 million. Capital expenditures for the third quarter were $21.3 million primarily related to our continued investment in increasing aligner capacity and facilities. Free cash flow defined as cash flow from operations less capital expenditures amounted to $189.8 million. Under our May 2018 repurchase program, we have $100 million still available for repurchase of our common stock.

    第三季營運活動現金流量為2.11億美元。第三季資本支出為2,130萬美元,主要與我們持續投資以提升隱形矯正器產能及設施相關。自由現金流(定義為營運活動現金流量減資本支出)為1.898億美元。依據我們2018年5月的庫藏股回購計畫,目前仍有1億美元可用於回購本公司普通股。

  • Now let me turn to our outlook. Overall, we're pleased with our Q3 performance and the strong momentum in our business. We made investment decisions that help drive and capture demand across all regions and all customer channels. We see good return on our investments and strong revenue growth, which has contributed -- has continued into October. We are confident in the huge market opportunity, our industry leadership and our ability to execute. At the same time, there continues to be uncertainty around the pandemic and global environment. Therefore, we aren't providing specific guidance.

    現在我來談談我們的展望。整體而言,我們對第三季表現以及業務的強勁動能感到滿意。我們做出投資決策,以協助在所有地區及所有客戶通路推動並掌握需求。我們看到投資帶來良好回報與強勁營收成長,且此趨勢已延續至10月。我們對龐大的市場機會、我們的產業領導地位以及執行能力充滿信心。同時,疫情與全球環境仍存在不確定性。因此,我們不提供具體指引。

  • With that, I'll turn it back over to Joe for final comments. Joe?

    接下來我把時間交回給Joe做最後評論。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, John. In summary, we're certainly pleased with our progress in the third quarter. We have taken a very thoughtful approach to recovery, and we've persevered in a large part by living the values that are important to us as an organization: agility, customers and accountability.

    謝謝,John。總結來說,我們對第三季的進展確實感到滿意。我們以非常審慎的方式推動復甦,而我們之所以能在很大程度上堅持下來,是因為我們實踐了作為組織所重視的價值觀:敏捷、以客戶為中心與問責。

  • In a time of great uncertainty when swift actions have been required, we've responded like no other company in our industry. Most importantly, we have followed our guiding principles and supported our employees and customers, protecting employee jobs and salaries and working to support the needs of our teams globally. And supporting our customers with PPE, extended payment terms, postponed subscription fees for iTero and numerous programs to help them through this crisis.

    在高度不確定、需要迅速行動的時期,我們的回應方式在業界無出其右。最重要的是,我們遵循指導原則並支持員工與客戶,保障員工工作與薪資,並努力支援全球團隊的需求。同時也以個人防護裝備(PPE)、延長付款條件、延後iTero訂閱費,以及多項計畫協助客戶度過這場危機。

  • We also applied our manufacturing experience and resources to making testing swaps for hospitals and PPE for our own terms, teams and also customers. Instead of going quiet or holding on a planned spend, we accelerated our investments in marketing to drive consumer demand to our doctors' offices and stay top of mind with consumers.

    我們也運用製造經驗與資源,為醫院製作檢測拭子,並為我們自身的診所、團隊以及客戶提供PPE。我們沒有選擇沉默或保留原先規劃的支出,而是加速行銷投資,以帶動消費者需求回到醫師診所,並在消費者心中維持高能見度。

  • We accelerated new technology to market so that we could provide virtual tools to our doctors that enable them to stay connected with their patients and keep their treatment moving forward. We supported doctors and their teams with online education and digital forums that went beyond product and clinical education to help to navigate the PPE shortages and recovery planning. And we continue to grow the business, not just protecting jobs but adding headcount, continuing our investments in R&D and product innovation, as you saw in our Invisalign G8 announcement today and developing our plans for manufacturing expansion.

    我們加速將新技術推向市場,讓我們能為醫師提供虛擬工具,使其得以與病患保持連結並推動治療持續進行。我們透過線上教育與數位論壇支持醫師及其團隊,內容不僅涵蓋產品與臨床教育,也協助他們因應PPE短缺與復甦規劃。我們也持續成長業務,不只是保住工作,更增加人力編制,持續投資研發與產品創新;正如你們今天看到我們發布Invisalign G8的公告,以及我們正在制定製造擴產計畫。

  • Our actions are a result of the convictions that we have in our business model, supported by the strength of our balance sheet to drive results that exhibit our accountability to our employees, customers and shareholders. Even in a time that required us to change and adapt, we maintained our long-term focus. I feel this is what good companies do. And it's proof of being a good company and delivering on the types of results we've seen this quarter can go hand in hand.

    我們的行動源自於對商業模式的堅定信念,並以資產負債表的強勁實力為後盾,推動成果,展現我們對員工、客戶與股東的問責。即使在需要改變與適應的時期,我們仍維持長期聚焦。我認為這就是好公司會做的事。而且也證明,成為一家好公司與交出本季這樣的成果,是可以相輔相成的。

  • We have remained a growth business, driving programs in anticipation of recovery, but we acknowledge that there still remains uncertainty due to COVID-19. Our plan is to counter future uncertainty by staying focused on our long-term strategy, living our values, supporting our employees and customers and keeping the demand drivers we've identified over the last few months in mind: the redirection of disposable income for many consumers; channel focus that allows us to reach and support a wider range of customers within each channel; and most importantly, the digital mindset that is really taking hold with more and more of our customers and that we are supporting through innovative products and programs that can help support their digital transformation.

    我們仍是一家成長型企業,推動各項計畫以迎接復甦,但我們也承認COVID-19仍帶來不確定性。我們的計畫是透過持續聚焦長期策略、實踐價值觀、支持員工與客戶,並牢記過去幾個月所辨識的需求驅動因素,以對抗未來的不確定性:許多消費者可支配所得的重新分配;通路聚焦,使我們能在各通路內觸及並支持更廣泛的客戶;以及最重要的,數位思維正被越來越多客戶所採納,而我們透過創新產品與計畫來支持其數位轉型。

  • We are not ignoring the reality of COVID-19 and how long it may be part of our lives. But we're also not going to stop driving the business forward for the good of customers, their patients, our employees and stakeholders.

    我們並未忽視COVID-19的現實,以及它可能在我們生活中存在多久。但我們也不會停止推動業務向前,為了客戶、他們的病患、我們的員工與利害關係人。

  • With that, I want to thank you again for joining our call. I look forward to updating you on our progress as the year continues to unfold. On November 20 to 21, Align will be hosting the Invisalign Ortho Summit, Virtual Edition with the theme, Digital is the Answer.

    最後,再次感謝各位參與本次電話會議。我期待在今年接下來的進展中,持續向各位更新我們的成果。11月20日至21日,Align將舉辦Invisalign Ortho Summit(虛擬版),主題為「Digital is the Answer」。

  • The Invisalign Summit is the ultimate learning experience for orthodontic practices. From digital practice transformation to great patient experience, there's never been a more exciting time to learn about digital orthodontics. Align will also host a Virtual Investor Day on November 23, where I also look forward to sharing our views on the incredible market opportunity that we have combined with the unmatched power of Align's digital platform, technology innovation, global reach and brand equity.

    Invisalign Summit是矯正科診所的終極學習體驗。從數位化診所轉型到卓越的病患體驗,現在正是了解數位矯正最令人振奮的時刻。Align也將於11月23日舉辦線上投資人日,屆時我也期待分享我們對巨大市場機會的看法,以及Align數位平台、技術創新、全球觸及與品牌資產所帶來的無可匹敵的力量。

  • Now with that, I'll turn it over to the operator for questions. Operator?

    接下來,我把時間交給接線員進行提問。接線員?

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Our first question comes from the line of Nathan Rich with Goldman Sachs.

    我們的第一個問題來自高盛(Goldman Sachs)的Nathan Rich。

  • Nathan Allen Rich - Research Analyst

    Nathan Allen Rich - Research Analyst

  • Joe and John, obviously, great to see the volumes come back so nicely. Sounds like the momentum continued in October. Could you maybe just, kind of, help us understand, kind of, the cadence of growth that you saw over the quarter? And any comments on how October has fared so far maybe relative to the type of case growth that you saw in 3Q?

    Joe和John,很高興看到量能回升得如此漂亮。聽起來10月動能也延續。你們是否可以協助我們理解一下本季你們看到的成長節奏?以及就目前10月的表現,是否能評論一下相較於第三季病例量成長的情況?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. Nathan, thanks for the question. Look, we just built through the quarter. Every month we saw, actually, continue to enhance momentum. And the short answer to your question is, we've seen that build in October also.

    是的。Nathan,謝謝你的問題。你看,我們整個季度是逐步建立起來的。每個月我們都看到動能持續增強。對你問題的簡短回答是:我們在10月也看到同樣的增勢。

  • Nathan Allen Rich - Research Analyst

    Nathan Allen Rich - Research Analyst

  • That's great. And Joe, obviously, you talked through in detail about what has driven the stronger utilization that you've seen in the value of digital treatment. When you take a step back and think longer term, how is that kind of change your outlook or influence your multiyear outlook for what you could see from this business over the next several years going forward?

    很好。Joe,顯然你已詳細說明你們所看到的更高使用率,以及數位治療價值所帶來的驅動因素。從更長期的角度退一步看,這樣的變化如何改變你們的看法,或影響你們對未來數年的多年期展望?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Nathan, you've known John and me, and Shirley really long enough. I mean we're incredibly enthusiastic about this business and bullish about this business. And you can see we're even more so as, obviously, we delivered the kind of results we have in 3Q. I think you always have to keep in mind 2 things here.

    Nathan,你認識John、我,以及Shirley也夠久了。我們對這項業務一直都非常熱情,也非常看多。而且你也看到,隨著我們在第三季交出這樣的成果,我們更是如此。我認為你必須始終記住兩件事。

  • One is we're in a very volatile environment. We understand that, and we've done some things we feel that's really helped our doctors through this and made the company stronger coming out at the other end.

    第一,我們處在一個非常波動的環境。我們理解這點,也做了一些我們認為確實幫助醫師度過這段期間、並讓公司在走出另一端時更強大的事情。

  • But always remember, we're completely under-penetrated in this marketplace, right? We're still less than 10% penetrated from an orthodontic procedure standpoint, let alone those 300 million patients we talk about there, that should receive orthodontic treatment that aren't receiving orthodontic treatment. So let me -- we remain incredibly bullish with a digital format to be able to go after those patients and be able to continue to drive the growth of this business.

    但請永遠記得,我們在這個市場的滲透率仍然非常低,對吧?從矯正療程的角度來看,我們的滲透率仍不到10%;更不用說我們常提到的那3億名應該接受矯正治療、卻尚未接受治療的病患。因此,我們仍然非常看多,因為透過數位化形式,我們能夠觸及這些病患,並持續推動這項業務的成長。

  • Operator

    Operator

  • Our next question comes from the line of Erin Wright with Credit Suisse.

    我們的下一個問題來自瑞士信貸(Credit Suisse)的Erin Wright。

  • Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

    Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

  • So can you speak to some of the contributions from the recovery efforts in switching brackets and wires in patients? Are you continuing to see those contributions and efforts into the fourth quarter? And do you think that will drive a more longer term shift here? Do you have any indication based on the responses, I guess, you've seen from practitioners, how sticky that is?

    你能否談談在復甦過程中,將病患從托槽與鋼線轉換過來所帶來的一些貢獻?你們在第四季是否仍持續看到這些貢獻與努力?你認為這會帶來更長期的轉變嗎?根據你們從臨床醫師那邊看到的回應,你們是否有任何跡象顯示這種轉變的黏著度有多高?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Well, it's -- overall -- hey, it's Joe. I mean overall, it's pretty sticky when we buy their wires and brackets inventory back. And then we introduced in the programs like ADAPT and different things. It will really allow them to begin a digital transformation within their practices. So I feel that part is very sticky.

    嗯,這——整體而言——嘿,我是 Joe。我的意思是,整體而言,當我們把他們的鋼絲與托槽庫存買回來時,黏著度相當高。然後我們也導入了像 ADAPT 以及其他不同的方案。這真的能讓他們在其診所內開始進行數位轉型。所以我覺得那一部分的黏著度非常高。

  • I can't sit here and naively say that everyone who starts to move digital in this crisis is going to stay digital. But I can tell you that we have the tools, being able to drive consumer demand and the consumer awareness and all those things helps us to maintain that stickiness. And I think over time, we'll just have to see how sticky it is as we come out of this COVID crisis.

    我不可能坐在這裡天真地說,在這場危機中開始轉向數位化的每個人都會一直保持數位化。但我可以告訴你,我們具備相關工具;能夠帶動消費者需求、提升消費者認知以及所有這些事情,都有助於我們維持這種黏著度。我想隨著時間推移,當我們走出這場 COVID 危機時,黏著度究竟有多高,我們只能再觀察。

  • Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

    Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

  • Okay. Great. And then on ASPs in the quarter, I guess, is that the run rate we should be thinking about? I know you didn't take the price hike, but any other mix dynamics then as we think about the next quarter and beyond?

    好的。很好。那關於本季的 ASP,我想問,這是否就是我們應該思考的運行水準(run rate)?我知道你們沒有調漲價格,但當我們思考下一季以及更往後時,是否還有其他產品組合(mix)動態?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. Erin, this is John. Yes, the mix that we saw, we talked about some of the dynamics of all those new cases coming in. And we saw that. We also talked about not having a price increase given the conditions that we're in. We'll evaluate going forward as to any changes we might make in pricing and so on. But I think from a run rate standpoint, this is a good starting point for going forward.

    是的。Erin,我是 John。是的,我們看到的組合變化,我們談到了一些新病例進來所帶來的各種動態,而我們也確實看到了。我們也談到在目前所處的情況下不進行漲價。往後我們會評估在定價等方面可能做出的任何調整。但我認為就運行水準而言,這是一個不錯的起點,可作為未來前進的基礎。

  • Operator

    Operator

  • Our next question comes from the line of Stephen Beuchaw with Wolfe Research.

    我們的下一個問題來自 Wolfe Research 的 Stephen Beuchaw。

  • Stephen Christopher Beuchaw - Director of Equity Research

    Stephen Christopher Beuchaw - Director of Equity Research

  • I wonder if you could expound a little bit on some of the numbers that you've given here this quarter, and I believe you did in the prior quarter as well, around not just the training numbers, but some of the data that you gave on people who are not just getting trained, but who are new to Invisalign. I'm sorry, I don't know it. Maybe some do, but what were those numbers a year ago? And do you have visibility into what those training numbers look like out into 4Q or even beyond?

    我想知道你是否能更深入說明一下你們本季提供的一些數字,我相信你們在上一季也有提到,不僅是培訓人數,還包括你們提供的某些數據:不只是接受培訓的人,還有那些對 Invisalign 來說是新加入的使用者。抱歉,我不太清楚——也許有些人知道——但一年前那些數字是多少?另外,你們是否能見度看到第 4 季甚至更往後的培訓人數會是什麼樣子?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. Steve, this is John. I think when you look at being able to train like we can now, doing much more virtual, be able to have that remote training as well as where you can in person, gives us a lot of flexibility going forward to be able to expand out our training. So there's a lot of new capabilities, a lot of new tools that we've introduced this quarter to be able to help our customers and train new customers as well as our sales team be able to reach those.

    是的。Steve,我是 John。我認為當你看我們現在能夠進行的培訓方式——更多採用虛擬形式,也能進行遠端培訓,並且在可行時也能面對面——這讓我們在未來擴大培訓方面具有很大的彈性。因此,我們在本季導入了許多新能力與新工具,來協助我們的客戶,培訓新客戶,同時也讓我們的銷售團隊能夠觸及這些對象。

  • So it's a key part, as you know, to our growth, and we're going to continue to find ways to be able to connect with new doctors to be able to get them to understand the benefits of Invisalign and ultimately have them use it more and more to grow.

    所以你也知道,這是我們成長的關鍵部分,我們會持續尋找方法與新的醫師建立連結,讓他們了解 Invisalign 的好處,最終讓他們越來越多地使用它以帶動成長。

  • Stephen Christopher Beuchaw - Director of Equity Research

    Stephen Christopher Beuchaw - Director of Equity Research

  • Okay. And then, Joe, one for you. So I'll let you carry the burden of being the CEO of the first big dental company here in the U.S. to report. Just give a little bit of perspective on how you imagine policy evolve.

    好的。接著,Joe,有一題給你。我就讓你承擔一下,作為美國第一家在這裡率先公布財報的大型牙科公司 CEO 的壓力。請你稍微分享一下你如何想像政策的演變。

  • As you talk to folks around the CDC, AAO, the ADA, any of their counterpart organizations in Europe, do you see any sign that there might be a move toward practice closures? Or are we really past that now that we've got PPE in place? I ask because I think there are just a lot of folks who are looking at the growth, not just at Align, but at some other companies, and it's really attractive growth, but people are just worried about the possibility that we see lockdowns again. So any perspective you could offer there would be really helpful.

    當你與 CDC、AAO、ADA 的人士,以及歐洲的對口組織交流時,你是否看到任何跡象顯示可能會再度走向診所關閉?還是說,既然我們已經有 PPE 到位,現在基本上已經過了那個階段?我之所以問,是因為我認為有很多人在看成長,不只是 Align,還有其他一些公司,成長看起來很吸引人,但大家擔心的是我們是否可能再次看到封鎖(lockdowns)。所以你能提供的任何觀點都會非常有幫助。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. Steve, I'd tell you, talking to, obviously, doctors all around the world or whatever. I don't see that there's any imminent a lot of closures in the industry. I mean there's frustration with the closures. And obviously, a lot of disagreement in the sense of when they're told to close. Fortunately, what we've seen with the COVID coming back here in the fall, we haven't seen the institution of going back and closing these doctors' offices, which help.

    是的。Steve,我會告訴你,和——很顯然——全球各地的醫師交流之後,我不認為這個產業會在短期內出現大量關閉。我是說,大家對關閉措施感到挫折,而且在被要求關閉的時點上,確實存在很多分歧。幸運的是,我們看到今年秋天 COVID 再度升溫時,並沒有看到又回到要求這些醫師診所重新關閉的情況,這是有幫助的。

  • I can tell you, Steve, since I've been here 5 years, there's always a certain segment of the dental industry that is looking to sell or looking to change and get out, but not close down. So I honestly think that there's still optimism out there. I've seen the doctors do a great job in a sense of being able to protect their employees, make sure that they protect their patients and do the things that are needed.

    我可以告訴你,Steve,我在這裡 5 年以來,牙科產業裡總是有一部分人想要出售、想要改變、想要退出,但不是把診所關掉。所以我坦白說,我認為外界仍然抱持樂觀。我看到醫師們做得很好,能夠保護員工、確保保護病患,並且完成所需的各項措施。

  • I know by reading your material and other materials that we've all picked up that most of the doctors are running at 70%, 75% kind of the capacity, but they're finding a way to make it work. So I'm not looking at any imminent demise in the business in the sense of close downs or anything like that. And I think the offices are getting better and better in being able to drive volume through their offices.

    我知道從你們的資料以及我們大家讀到的其他資料來看,多數醫師的營運大概在 70%、75% 這樣的產能水準,但他們正在想辦法讓它運作起來。所以我不認為短期內會出現任何業務上的崩潰,例如關門之類的。我也認為診所在推動門診量(volume)方面正變得越來越好。

  • And again, you know that this is the digital format that we feel that sets a foundation for them to have a much better patient flow through and much fewer touches in this COVID world, which we hope -- hopefully will carry over as we move out of this next year.

    再者,你也知道,我們認為這種數位化形式為他們奠定了基礎,讓病患流程能更順暢、接觸點更少,在這個 COVID 的世界裡尤其如此;我們希望——也但願——當我們明年走出這段期間時,這些做法仍能延續。

  • Operator

    Operator

  • Our next question comes from the line of Jon Block with Stifel.

    我們的下一個問題來自 Stifel 的 Jon Block。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • Joe, actually, first one for you. Sort of qualitatively, can you give us a beat or a signal on teen share of chair? And do you see it broadening out within your ortho customer base? I think that's the key sort of the broadening out. In other words, are you seeing the one from orthos that were always, I don't know, call it, less than 5% Invisalign share of chair? Are they stepping up to the play because the clear aligner workflow advantages? And if so, how do you sort of ensure that you capitalize on that longer term?

    Joe,第一題其實是給你的。從質性的角度,你能否給我們一些關於青少年「椅旁占比」(share of chair)的趨勢訊號?你是否看到它在你們的矯正客戶群中擴大?我認為關鍵在於這種擴大。換句話說,你是否看到那些矯正醫師——他們過去 Invisalign 的椅旁占比一直很低,我不知道,可能不到 5%——因為透明牙套工作流程的優勢而開始加大投入?如果是,你們要如何確保能在長期把握住這個機會?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. Well, I think there's a couple of things. John, obviously, COVID has been an additive incentive to move people out of analog and into digital because of fewer touches and being able to maintain continuity of treatment even if things were shut down. So there's no question, we saw a share of chair increase in that sense.

    是的。嗯,我認為有幾件事。Jon,很顯然,COVID 提供了一個額外的誘因,讓人們從類比流程轉向數位流程,因為接觸點更少,而且即使在停業的情況下也能維持治療的連續性。所以毫無疑問,我們確實在那個意義上看到椅旁占比提升。

  • I think also when you see new products like Invisalign First and those things we've introduced in the last few years, that's -- as you know well, that's extended our reach from an age standpoint within that specific demographic. That's helped us also.

    我也認為,當你看到像 Invisalign First 以及我們過去幾年推出的那些新產品時——你很清楚——那從年齡層的角度擴大了我們在特定族群中的觸及範圍,這也對我們有所幫助。

  • And I think there's a combination here of further and further realization of how digital processes in orthodontics really can help, can help be more efficient. But also a realization from consumers that it is an offering here that is better than wires and brackets and more efficient, certainly in this COVID, kind of, environment.

    我認為這裡有一個組合因素:大家越來越認知到,矯正領域的數位流程確實能帶來幫助、能提升效率。同時,消費者也意識到,這是一種比鋼絲與托槽更好的選擇,而且更有效率,尤其是在這種 COVID 的環境之下。

  • So how do we -- how are we certain that we maintain that? So when you look at programs like ADAPT and things, those -- let's switch over. Let's back up for a second, John. 5 years ago, we were fighting for a clinical, I'd say, relevancy in this industry. That's not a question anymore. Most of the docs out there understand very clearly, we can do 80%, 90% of the cases out there. It becomes a business formula. Can we really make money with a digital kind of a system?

    那我們要如何——如何確保能維持這點?所以當你看像 ADAPT 這類方案以及其他事情時——讓我們先切換一下。Jon,我們先退一步說。5 年前,我們在這個產業裡還在爭取臨床上的——我會說——相關性(relevancy)。現在這已經不是問題了。大多數醫師都非常清楚,我們可以處理市面上 80%、90% 的病例。接下來就變成一個商業公式:用這種數位系統,我們真的能賺錢嗎?

  • And those are the programs that we've been putting together with doctors, with outside experts that can really train doctors as to how digital can work, how it can expand their practices and how that actually can be more profitable in a digital processing. I'm confident with what we're building up in that area, we'll be able to extend that going forward.

    而這正是我們一直在與醫師、以及外部專家一起建立的方案:能夠真正訓練醫師了解數位化如何運作、如何擴大他們的診所,以及在數位流程下如何實際變得更有利可圖。我對我們在這方面所建立的內容很有信心,我們將能在未來持續擴展。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • Got it. Fair enough. And I'll shift over to GP side for the other question, the utilization number 4, I think I've been waiting for 10 or so years for that. And I get it. Some of it's probably pent-up demand. You talked to that a little bit on the call, but what about the other components? Is it some scanner, digitizing the front end, the bifurcating of the sales force?

    了解。很合理。那我把另一題轉到 GP(一般牙醫)端:利用率(utilization)數字到 4,我想我等了大概 10 年左右才看到。我明白,其中一部分可能是被壓抑的需求。你們在電話會議上也稍微談到了,但其他構成因素呢?是否包括一些掃描器、前端流程的數位化、以及銷售團隊的分流(bifurcating)?

  • I mean essentially, Joe, have you given the tools that you needed to the GP to finally sort of step function that utilization rate higher? That was always sort of stuck right around that mid-3s for a number of years.

    我的意思是,基本上,Joe,你們是否已經把GP(一般牙醫)所需要的工具都提供到位,讓那個使用率最終能夠算是「跳升」到更高的水準?因為多年來它一直卡在大約3%中段左右。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. Jon, I feel the answer your question is, yes, we have. I mean everything from iTero and really the insides of iTero and the software programs and all, in conjunction with iGo, is that make it much simpler for doctors that haven't been associated with digital orthodontics before.

    是的。Jon,我覺得你問題的答案是:是的,我們已經做到了。我的意思是,從 iTero、iTero 的內部功能、軟體程式等等,再結合 iGo,這些都讓以前沒有接觸過數位矯正的醫師使用起來簡單得多。

  • Our segmented sales force, for sure. I mean we piloted this in Europe first and somewhat in APAC. So we knew what to expect. We are just fortunate enough to launch it ahead of this issue -- ahead of the COVID issue and to have the salespeople ready to have that touch with customers to make it work.

    我們的分眾化銷售團隊當然也是。我是說,我們先在歐洲做了試點,也在亞太地區(APAC)某種程度上做了試點,所以我們知道可以期待什麼。我們很幸運能在這個問題——在 COVID 問題之前——就提前推出,並且讓業務人員準備好能與客戶保持那種接觸,讓它運作起來。

  • What I'm excited about this, Jon, we have so much more that we can do to make that work also. And I think with the confidence that GPs are having in this kind of a system, it's a light touch system. It's a high revenue, kind of, a product, and it's gaining more attention in that channel. So yes, I'm really -- we're all thrilled here to see the utilization rates. But it is on the back of those kind of innovations in distribution and also product that we think we've been able to drive it.

    Jon,讓我對這件事感到興奮的是,我們還有更多可以做、也能讓它更有效。我認為,隨著GP對這類系統的信心提升——這是一個「輕接觸」的系統,是一個高營收、算是產品類型,而且在那個通路正獲得更多關注——所以是的,我真的——我們大家都很振奮能看到使用率。但這是建立在我們在通路與產品上的這類創新之上,我們認為正是這些推動了它。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • Okay. And if I could just quickly slip in one more. Just for a clarification, I think it was all the way back to Nathan's first question. Just to be clear, when you say momentum building, I mean, do we take that your October year-over-year growth rate was north of your worldwide 3Q growth rate that you posted?

    好的。如果我可以再快速插入一個問題做澄清,我想那要追溯到 Nathan 的第一個問題。為了確認一下,當你說動能正在建立時,我的意思是,我們是否可以理解為你們10月的年增率高於你們公布的全球第三季(3Q)年增率?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Jon, we -- you're right, we are -- we see momentum building. And that continues -- it continues that growth from a revenue and a volume standpoint into October.

    Jon,我們——你說得對,我們——我們看到動能正在建立。而且這個趨勢持續——從營收與出貨量(volume)的角度來看,這個成長延續到了10月。

  • Operator

    Operator

  • Our next question comes from the line of Elizabeth Anderson with Evercore.

    我們的下一個問題來自 Evercore 的 Elizabeth Anderson。

  • Elizabeth Hammell Anderson - Associate

    Elizabeth Hammell Anderson - Associate

  • As we think about the outlook for 4Q and as we come out of COVID more broadly, are there any -- I know you guys were obviously didn't cut costs, kept the sales force because you maybe foresaw some of this growth coming back. Is there anything in terms of investments of the ramp back that we should be considering?

    當我們思考第四季(4Q)的展望,以及更廣泛地走出 COVID 之後,有沒有任何——我知道你們顯然沒有削減成本、也保留了銷售團隊,因為你們可能預見到部分成長會回來。那在投資或復甦爬坡(ramp back)方面,有沒有什麼是我們應該納入考量的?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Well, there's a bit -- I think we're just -- there's continuity of investments is the way I'd answer your question. They're not new investments. We'll continue to invest in the consumer side pretty dramatically. You'll see that we're doing that all around the world. It's not just in the United States or Canada. We're also -- you'll see investments in Europe and also Asia to a degree that we haven't made before.

    嗯,有一點——我想我會用「投資的延續性」來回答你的問題。這些不是新的投資。我們會持續在消費者端相當大幅度地投資。你會看到我們在全球各地都在做,不只是美國或加拿大。我們也——你會看到我們在歐洲、以及在亞洲某種程度上投入到我們以前沒有做過的程度。

  • We have a series of new products that we're investing in that we kept that momentum in the third quarter and where we hired engineers to keep that moving. And then these specific programs for doctors like ADAPT that we're talking about, an AIF and different things, they're really an important part of this because you have to make sure that these workflow changes and the way ClinCheck works, like ClinCheck Pro, whatever, they have to be introduced to docs. And you got to have a high-touch kind of a system to give them the confidence in those programs.

    我們正在投資一系列新產品;第三季我們維持了那個動能,也聘請工程師讓它持續推進。然後,像我們提到的 ADAPT、AIF 以及其他不同項目,這些針對醫師的特定計畫也非常重要,因為你必須確保這些工作流程的改變、以及 ClinCheck 的運作方式(例如 ClinCheck Pro 等等)能被介紹給醫師。你需要一套高接觸(high-touch)的系統,讓他們對這些計畫建立信心。

  • So it's a long answer to your question, but I'd say we maintain and enhance what we have been doing is what you'll see in the fourth quarter and as we go into the first quarter, too.

    所以這是個比較長的回答,但我會說,你會在第四季以及進入第一季時看到的是:我們維持並強化我們一直在做的事情。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • The added piece, Elizabeth, from an investment standpoint is investing in operations to stay ahead of the volume and making those investments. We did so in Q3, we'll continue to make those investments in Q4.

    Elizabeth,從投資角度來看,另外一塊是投資營運(operations),以便在出貨量之前保持領先並進行那些投資。我們在第三季已經這麼做了,第四季也會持續進行這些投資。

  • Elizabeth Hammell Anderson - Associate

    Elizabeth Hammell Anderson - Associate

  • Okay. But it doesn't sound like there's anything totally different that the sort of -- because we could consider catch up for something on that front?

    好的。但聽起來似乎沒有什麼完全不同的、那種——因為我們可能會把它視為在那方面的「補進度」(catch up)?

  • Okay. I guess, and then...

    好的。我想,然後……

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • No. I don't think... go ahead, Elizabeth.

    沒有。我不認為……你繼續,Elizabeth。

  • Elizabeth Hammell Anderson - Associate

    Elizabeth Hammell Anderson - Associate

  • No. I was just wondering, just -- you talked about some of your continued spend on social channels in terms of marketing, and that seemed also a continuation plus, obviously, the back program in the quarter. Is there anything else that you guys see changing in terms of your marketing spend going forward? Or do you see it's sort of like a continuation of the types of programs that you were doing in the third quarter?

    沒有。我只是想問一下——你提到你們在行銷上持續在社群渠道投入,這看起來也是延續性的,另外當季也有回補(back program)計畫。那未來在行銷支出方面,你們還看到有什麼其他變化嗎?還是你們認為這大致上就是延續第三季所做的那些類型的計畫?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Well, I think obviously, Raj and our marketing team are very innovative. And it's not that we'll just keep with the same themes. We'll -- we obviously -- we run trials, we do different things. We'll change them up or whatever, based on what we're experiencing in the marketplace. So our investments will continue to be very aggressive. We'll continue to be innovative in the sense of how we do these things. But we certainly won't let off the gas in the sense of the focus that we've had over the last few quarters.

    嗯,我想很明顯地,Raj 和我們的行銷團隊非常有創新力。並不是說我們只會維持相同的主題。我們——很明顯地——我們會做測試、做不同的事情,並根據我們在市場上看到的情況去調整或更換。所以我們的投資會持續非常積極;在我們做這些事情的方法上也會持續創新。但就我們過去幾季的聚焦程度而言,我們當然不會鬆油門。

  • Operator

    Operator

  • Our next question comes from the line of Steve Valiquette with Barclays.

    我們的下一個問題來自 Barclays 的 Steve Valiquette。

  • Jonathan Yong - Research Analyst

    Jonathan Yong - Research Analyst

  • This is Jonathan Yong on for Steve. So just in relation to the backlog that you were talking about and the pent-up demand, I guess from your perspective, how much backlog do you think is, kind of, still out there with the docs before kind of normal -- before it normalizes that as we kind of move forward?

    我是代 Steve 提問的 Jonathan Yong。關於你們提到的積壓訂單(backlog)與被壓抑的需求(pent-up demand),我想從你們的角度來看,你們認為在醫師端大概還有多少積壓量仍然存在,直到——在我們往前走、它回到正常之前?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • You asked a big question. I mean from a backlog standpoint, we really don't know. When you talk -- from an empirical standpoint, when you talk to any of our docs, they cleared out their backlog in July and August from -- this is a global business. It's hard to talk about all over the world where it stands, but -- and when things came out of lockdown and when they didn't. So we've struggled to be able to quantify a number for you in that sense.

    你問的是個很大的問題。就積壓訂單而言,我們其實不知道。從實證(empirical)的角度來看,當你和任何一位醫師交流,他們在7月和8月就把積壓清掉了——但這是全球性業務,很難談全世界各地目前的狀況,因為——各地何時解封、何時沒有解封都不同。所以我們一直很難在這個意義上為你量化一個數字。

  • Jonathan Yong - Research Analyst

    Jonathan Yong - Research Analyst

  • Okay. And just going back to the comment about the utilization of docs being at about 70%, 75% capacity. I guess from -- that's from the capacity standpoint. But from your customer base, are they all largely open at this point? Or is there still 10%, 20% that still remains closed due to random shutdowns globally or locally in certain areas?

    好的。再回到你提到醫師的使用率大約在70%、75%產能的評論。我想那是從產能角度。但從你們的客戶基礎來看,他們目前大多都已經開業了嗎?還是仍有10%、20%因為全球或某些地區的零星停業而仍然關閉?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • No, they're largely open.

    沒有,他們大多都已經開業了。

  • Operator

    Operator

  • Our next question comes from the line of John Kreger with William Blair.

    我們的下一個問題來自 William Blair 的 John Kreger。

  • John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services

    John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services

  • Can you just talk a little bit more about, again, the uncertainties that prompted you to not guide to Q4 after a very, very good third quarter? And one thing I was thinking about, given the rebound in cases in Europe, are you seeing any sign of, maybe, just patient traffic slowing down even if practices aren't closing per se?

    你能否再多談一點,究竟是哪些不確定性促使你們在第三季非常、非常好的表現之後,仍選擇不對第四季提供指引?我想到的一點是,考量歐洲病例反彈,你們是否看到任何跡象,例如即使診所不一定關閉,但病患就診人流可能在放緩?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. I think, John, when you think about what we've seen in terms of the momentum we see, we try to lay that out. Obviously, there are still unknowns in the world. I would say, COVID and the global economy and so on. But for the things that we can control and what we tried to lay out around the R&D investments in manufacturing and marketing and sales, we feel really good about our momentum and what we can drive in the future.

    是的。我想,John,當你思考我們所看到的動能時,我們試著把它說清楚。很明顯地,世界上仍然有未知數。我會說,包括 COVID、全球經濟等等。但就我們能控制的事情,以及我們試著說明的研發投資、製造、行銷與銷售等面向,我們對我們的動能以及未來能推動的成長感到非常有信心。

  • We just have unknowns that are outside of our control. And so that's the reason from a guidance standpoint that we didn't give specific guidance. And -- but we wanted to highlight that we saw continued momentum as we went through the quarter, both for revenue and volume and that continued past the quarter end.

    只是我們仍有一些不在我們控制範圍內的未知數。因此,從提供指引的角度來看,這就是我們沒有給出具體指引的原因。而且——但我們想強調的是,我們在整個季度中看到動能持續,不論是營收還是出貨量,而且這個趨勢在季末之後仍然延續。

  • John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services

    John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services

  • Great. Joe, a question for you about sort of the strategy to get the attention more of GPs. Can you just talk about how exocad is going? And what else you -- what other levers you're pulling to sort of become more of that daily thought process for the typical general dentist?

    很好。Joe,我有一個關於吸引更多GP注意力的策略問題。你能談談 exocad 的進展嗎?以及你們還在拉動哪些槓桿,好讓你們更成為一般全科牙醫日常思考的一部分?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. John, it's a good question. Look, I feel great about exocad. And obviously, what I talked about in my -- in the highlights that we just went over is, I mean it's digital dentistry on the GP side. And you have to go around the world to understand how exocad is. exocad is very embedded in Europe, also in various parts of the Far East and in some parts of the United States. But the key is just a digital workflow. And it's between -- iTero fronts this. It's in a -- obviously, a GP's office, and that CAD/CAM piece is either extended in office or primarily it goes to labs.

    是的,John,這是個好問題。你看,我對 exocad 的表現感到非常好。很明顯地,我在剛才回顧的重點中談到的是——我的意思是,這是在GP端的數位牙科。你必須走訪全球才能理解 exocad 的狀況。exocad 在歐洲非常深入,也在遠東的多個地區,以及在美國的部分地區相當普及。但關鍵就是數位化工作流程。而這是在——iTero 作為前端;它在——很明顯地——在GP的診所裡,而那個 CAD/CAM 的部分要嘛在診所內延伸,要嘛主要是送到技工所(labs)。

  • It's given us -- I think it's given us the initial boost that we wanted to in the sense of our relevancy in the GP's office, in the sense of an iTero scanner can do these kind of restorative scans and this kind of restorative workflow.

    這帶給我們——我認為這帶給我們我們所希望的初始推力,體現在我們在一般牙科(GP)診所中的相關性上,也體現在 iTero 掃描儀能夠進行這類修復掃描以及這類修復工作流程上。

  • What's really exciting is when you look at how you can integrate what exocad does in a seamless workflow way with iTero and also Invisalign, it just gives us a lot of degrees of freedom to really change that kind of restorative dentistry and I'm really excited about the progress even in a short amount of time.

    真正令人興奮的是,當你看到如何把 exocad 在無縫工作流程的方式下與 iTero 以及 Invisalign 整合起來時,這讓我們擁有很大的自由度,能夠真正改變那種修復牙科,而我對即使在很短時間內所取得的進展也感到非常興奮。

  • Operator

    Operator

  • Our next question comes from the line of Brandon Couillard with Jefferies.

    我們的下一個問題來自 Jefferies 的 Brandon Couillard。

  • Brandon Couillard - Equity Analyst

    Brandon Couillard - Equity Analyst

  • Joe, I think you said leads were up something like 120% year-over-year. How do we think about the relevancy of that metric as a leading indicator of revenue growth? It's not a metric I can recall you really discussing before.

    Joe,我想你說潛在客戶(leads)年增大約 120%。我們該如何看待這個指標作為營收成長的領先指標之相關性?這不是我記得你以前真的討論過的指標。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Well, it's a good question. I mean we do -- I don't know how we we've communicated that before, but it certainly is a term we use internally here at Align all the time. And a lead is just what you would guess it is, Brandon. It's a strong lead in a sense of a customer wanting to turn into a patient. And we have several ways of touching that customer.

    嗯,這是個好問題。我是說,我們——我不確定我們以前是怎麼對外溝通的,但這確實是我們在 Align 內部一直使用的術語。Brandon,所謂 lead 就如你所想的那樣:在某種意義上是一個強烈的線索,代表某位客戶有意願轉化為病患。而我們有好幾種方式可以觸達這位客戶。

  • They can come through our Invisalign app. They could be contacted by a concierge service. Concierge service can take the information and move it on to a doctor's office. But it's a lead and it's a great leading indicator of the interest of patients out there. And it's, again, one of the major attributes of Align and what we bring to the marketplace is to be able to excite consumers and move them into our doctor partner groups.

    他們可能透過我們的 Invisalign 應用程式進來;也可能由禮賓(concierge)服務聯繫。禮賓服務可以取得資訊並轉交到醫師診所。但這就是一個 lead,而且它是衡量外部病患興趣的一個很好的領先指標。而且再次強調,Align 的主要特質之一、也是我們帶給市場的價值,就是能夠激發消費者並把他們導入我們的醫師合作夥伴群。

  • Brandon Couillard - Equity Analyst

    Brandon Couillard - Equity Analyst

  • Okay. And then John, any chance you could specifically speak to China growth in the third quarter? And then secondly, the financial impact of opening the new permanent manufacturing facility as opposed to the temporary site you have been operating, be it in terms of revenue growth or profitability expenses, anything you can share there?

    好的。接著 John,你能否具體談談第三季中國的成長?其次,啟用新的永久製造工廠相較於你們一直在運作的臨時據點,其財務影響為何——不論是對營收成長或獲利、費用等方面,有任何可以分享的嗎?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • In China, we saw a good sequential growth, continues to grow. I mean, obviously, they were the first ones, kind of, in the pandemic to start in Q1. We saw some growth in Q2 and significantly more growth in Q3.

    在中國,我們看到不錯的季增,且持續成長。我的意思是,很明顯地,他們在疫情期間算是第一批在第一季開始(受影響/啟動)的。我們在第二季看到一些成長,而第三季的成長顯著更多。

  • The manufacturing, like you said, has gone live. It's now a greenfield facility where everything is up and running. We're adding more capacity there to meet our demands, but it was a very smooth transition. We learned a lot from having that temporary facility and learning kind of the manufacturing, the scale-up that we needed and that transitioned very well into the new facility.

    製造方面,如你所說,已經正式上線。現在是一座綠地(greenfield)工廠,所有設備都已啟動並運轉。我們正在那裡增加更多產能以滿足需求,而且過渡非常順利。我們從臨時工廠學到很多,了解我們所需要的製造與擴產規模,並且非常順利地轉移到新工廠。

  • Operator

    Operator

  • Our next question comes from the line of Jeff Johnson with Baird.

    我們的下一個問題來自 Baird 的 Jeff Johnson。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • So Joe, I wanted to start with you and the same thing Jon Block is trying to feel out here. But on -- was there anything different in your North American ortho customer mix? Did the Diamond and double diamond guys come back much faster than the lower end guys, anything at all like that?

    Joe,我想先從你這邊開始,這也是 Jon Block 想要釐清的同一件事。不過在——北美矯正客戶組合方面有沒有任何不同?Diamond 和 Double Diamond 的醫師是否比低階層級的醫師回來得快很多?有沒有任何類似的情況?

  • And I guess what I'm trying to get at the same thing, like I said, John, is sustainability of that 24% North American ortho utilization number, a fantastic number, is that our evidence? Is that our proof point there of this move from analog to digital as you keep talking about it? Is that the number to focus in on there, and obviously, the GP number as well?

    我想追問的其實也是同一點,如我所說,John,是關於北美矯正 24% 的使用率(utilization)數字能否持續——這是個很棒的數字。這是否就是我們的證據?是否就是你一直在談的從類比到數位轉移的驗證點?是否應該把焦點放在這個數字上,當然還有 GP 的數字?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. I think if you're -- Jeff, if your real question is about utilization being a key metric, I mean, it certainly is. Now who led that? Our Diamond, Diamond Plus docs already have a big digital aspect of what they were doing. We're able to function extremely well in this environment.

    是的。我想如果——Jeff,你真正的問題是使用率是否是一個關鍵指標,我的意思是,它確實是。那麼是誰帶動的?我們的 Diamond、Diamond Plus 醫師本來就有很高的數位化比重。他們在這樣的環境下能夠運作得非常好。

  • Remember, our virtual care tool that we wrote out really 6 months before we wanted to do it. It wasn't the best tool in the world, but we've made it better over time, really given that digital interface with their patient base that allow them to be able to track their patients without having to come back to the office that was closed or (inaudible) at the time.

    記得我們的虛擬照護工具其實比原本計畫提前了大概 6 個月推出。它不是世界上最好的工具,但我們隨著時間讓它變得更好,真正提供了與病患群之間的數位介面,使他們能夠追蹤病患,而不必回到當時關閉或(聽不清)中的診所。

  • So -- but to say that it was only those practices would be wrong. We saw -- no matter what tier they were in our advantage program, we saw them reaching for training, wanting to work from a digital standpoint, the orthodontist to recognize the advantages of digital doing this whole sequence. And again, that's why the program and the things that we've had in place, the investments we made or whatever, they were very timely to help to support that interest.

    所以——但如果說只有那些診所才這樣就不對了。我們看到——不論他們在我們 Advantage 計畫中屬於哪個層級,我們都看到他們在尋求訓練、希望以數位方式工作;矯正醫師也認知到以數位方式完成整個流程的優勢。再說一次,這就是為什麼我們已經建立的計畫與各項措施、我們所做的投資等等,都非常及時,能夠支援這股興趣。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Yes. Understood. And then maybe just a follow-up for John. So John, you seem to imply that maybe ASPs here at this level are a good way to think about the next few quarters. Does that mean some of the incentives, kind of, sustain here? Do you leave them in place and I just want to understand the accounting. Does the bracket buybacks, does that go against ASPs in any way? Or is that a cost buried somewhere else in the P&L?

    是的,了解。接著也許給 John 一個追問。John,你似乎暗示接下來幾季可以用目前這個 ASP 水準來思考。這是否表示某些激勵措施會在這裡維持?你們會把它們保留在位嗎?我想了解會計處理:托槽回購(bracket buyback)是否會以任何方式影響 ASP?還是那是一項被埋在損益表其他地方的成本?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • No. That is a cost against the -- as a promotion. So it goes against revenue for the bracket buyback. And we'll evaluate as we do on a normal basis with promotions, what promotions are working, what's driving that right level of utilization and engagement, whether you're a new doctor to a doctor that does a lot of volume.

    不。那是一項作為促銷的成本,所以托槽回購會沖減營收。我們會像平常一樣評估促銷:哪些促銷有效、哪些能推動適當的使用率與參與度——不論你是新醫師或是量很大的醫師。

  • We did mention that we didn't increase price. And that was something that's a reflection of what's happening in the marketplace. And look, we were very pleased with -- when you look at Invisalign ASPs, it's at 74.7%. We haven't seen that in several quarters. So we're very aware of the dynamics around promotions and what that drives. But ultimately, it's driving profitability and we saw great gross margin growth.

    我們確實提到我們沒有漲價,而這反映了市場上正在發生的情況。你看,當你看 Invisalign 的 ASP 時,它在 74.7%。我們已經好幾季沒看到這個水準了。所以我們非常清楚促銷的動態以及它所帶來的影響。但最終,它正在推動獲利能力,而我們也看到毛利率大幅成長。

  • Operator

    Operator

  • Our next question comes from the line of Glen Santangelo with Guggenheim.

    我們的下一個問題來自 Guggenheim 的 Glen Santangelo。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Glen are you there? Maybe we're not hearing your line clearly.

    Glen,你在線上嗎?也許我們沒有清楚聽到你的線路。

  • Glen Joseph Santangelo - Analyst

    Glen Joseph Santangelo - Analyst

  • Hello, can you hear me now?

    你好,現在聽得到我嗎?

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Yes.

    是的。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes, we can.

    是的,我們聽得到。

  • Glen Joseph Santangelo - Analyst

    Glen Joseph Santangelo - Analyst

  • Joe, I just want to take a step back. I mean a lot of the questions were already asked, but I wanted to follow-up to a response you said to an earlier question. What's your sense going on with the organic growth rate of this business? I mean are you seeing the organic growth rate or just in ortho business in general, accelerate through the pandemic?

    Joe,我想先退一步看。我是說,很多問題都已經被問過了,但我想針對你先前回答某個較早問題時的一段回應追問。你對這項業務的有機成長率(organic growth rate)目前的狀況有何看法?我的意思是,你是否看到有機成長率——或只是矯正業務整體——在疫情期間加速?

  • And then as you think about sort of the penetration of clear aligners versus total cases, you sort of cited that you still think were less than 10% penetrated. Can you maybe talk about the penetration in North America and international, and maybe how you see those sort of penetration rates evolving over the next couple of years?

    然後,當你思考透明牙套相對於總病例的滲透率時,你提到你仍認為滲透率不到 10%。你能否談談北美與國際市場的滲透率,並且談談你如何看待這些滲透率在未來幾年內的演變?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Well, I mean, we -- obviously, we measure ourselves from a penetration rate standpoint overall. And we split the market up, obviously, in teens and adults, ortho versus the general segment with GPs. But if I'm answering your question right, Glen, I mean we have increasing penetration and utilization we call in different parts of the marketplace. The digital platforms and things that we've put in place are really enhancement to doctors to get on these digital platforms and use the tools and things that we have.

    嗯,我是說,我們——很明顯地——會從整體滲透率的角度衡量自己。我們也把市場拆分,顯然分為青少年與成人、矯正專科(ortho)與一般牙科(GP)等區隔。但如果我正確理解你的問題,Glen,我的意思是,我們在市場不同部分看到滲透率與我們所稱的使用率在提升。我們建立的數位平台與各項措施,確實是在強化醫師採用這些數位平台並使用我們的工具與各項功能。

  • So Glen, I think, again, as I mentioned in the other question on -- like this is that, remember, we're so underpenetrated. It really is. Digital orthodontics has such a long runway. But it is a different workflow for doctors, and it's a different expectation from a patient base, understanding you really can use digital plastic in order to move teeth as efficiently or better than wires and brackets.

    所以 Glen,我想,再次如我在另一個問題中提到的——就像這樣,記得我們的滲透率仍然非常低,確實如此。數位矯正有非常長的成長跑道。但對醫師而言,這是一種不同的工作流程;對病患群而言,也是一種不同的期待——理解你確實可以用數位塑料來移動牙齒,其效率可與鋼絲與托槽相當甚至更好。

  • And so, it's so important that we have a strong digital platform that unites the workflow between us and doctors and doctors and patients that you have a breadth of product. Everything from Invisalign First all the way to Express and comprehensive products and retainers and things in between. Sales forces are incredibly important for that penetration in the sense of how you touch docs and how you move things forward.

    因此,我們擁有一個強大的數位平台來串聯我們與醫師、以及醫師與病患之間的工作流程非常重要;同時你也需要廣泛的產品組合——從 Invisalign First 一直到 Express、全方位(comprehensive)產品、維持器(retainers)以及其間的各種產品。銷售團隊對於提升滲透率也極其重要,因為這關係到你如何觸達醫師、以及如何推動事情向前。

  • So there's -- I would say, Glen, to answer your question here, there's no magic on this penetration piece. It's a lot of work. It's a lot of work and a lot of friction you have to overcome. There's no escaping it. But it's inevitable. Digital is better than analog in a COVID environment or not in the COVID environment. That's our position and that's what we'll continue to drive.

    所以我會說,Glen,為了回答你的問題,在這個滲透率的部分沒有什麼魔法可言。這需要大量的工作。你必須克服大量的工作與摩擦,無可避免。但這是必然的。不論是在 COVID 環境或非 COVID 環境,數位都比類比更好。這就是我們的立場,也是我們會持續推動的方向。

  • Glen Joseph Santangelo - Analyst

    Glen Joseph Santangelo - Analyst

  • And Joe, it seems like you maybe expanded your sort of technology lead again with sort of this latest development on the G8 side. Could you maybe just give us a quick update on the competitive landscape? Are you seeing anything else in the market that that is starting to get any traction? Or is it still kind of really just an execution issue for you?

    Joe,看起來你可能又在技術領先上進一步拉開差距,尤其是這次在 G8 方面的最新進展。你能否簡單更新一下競爭態勢?你是否看到市場上還有其他東西開始獲得一些動能?還是對你們而言,仍然主要是執行面的問題?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • This is all about execution with us. It's a -- from a -- I have nothing from an update from a competitive standpoint, really to report. Remember, our competition is about expanding the marketplace. That is what it's all about.

    對我們來說,這完全是執行的問題。從競爭面的角度來看,我其實沒有什麼更新可以報告。請記得,我們所謂的競爭,是在於擴大市場。這才是重點。

  • This is not a scrum of a bunch of people making plastic aligners. This is the scrum about what can you do to reduce the friction of getting dentists and orthodontists to move forward in the digital process. It's the growth of this marketplace that is really the material difference here. It's not individual competition and the trenches that we're focused on or concerned about how do we expand the marketplace, Glen.

    這不是一群人搶著做塑膠牙套的混戰。真正的戰場在於:你能做什麼來降低摩擦,讓牙醫與矯正醫師願意在數位流程上往前走。這個市場的成長,才是關鍵且實質的差異。我們關注的不是個別競爭、也不是壕溝戰;我們關心的是如何擴大市場,Glen。

  • Operator

    Operator

  • Our next question comes from the line of Richard Newitter with SVB Leerink.

    我們的下一個問題來自 SVB Leerink 的 Richard Newitter。

  • Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst

    Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst

  • I wanted to just start off, just looking back over the 20-year journey that you had or longer than that now. Well, you're not specifically, but just in aligners and what you've seen in your tenure and what you know before you. Can you -- there have probably been inflection point moments. And I'm just curious where and how kind of this COVID opportunity, which is clearly, on some level, creating an inflection point on some level. Where this stacks up?

    我想先從回顧你們 20 年、甚至更久的歷程談起。當然不是指你個人,但就隱形牙套這個領域,以及你在任內所見、以及你在你之前所了解的情況。這當中應該有一些關鍵的拐點時刻。我很好奇,這次 COVID 的機會顯然在某個層面上正在形成一個拐點。你覺得它在這些拐點中大概處於什麼位置?

  • A year or 2 years from now, do you think we're going to be saying this was probably the -- one of the defining periods for you guys to capitalize on converting the team segment and getting that accelerated kind of digital boost that you needed to really kind of move this market conversion opportunity in a set function fashion? I'm just trying to put it in perspective. Are we kind of at the demarcation here, in your view, where this is kind of defining period for the company?

    一年或兩年後,你覺得我們會不會說,這可能是你們把握住、用來加速轉換「團隊」這個區隔、並取得你們所需要的那種加速數位推進的關鍵時期之一,從而以階梯式的方式推動這個市場的轉換機會?我只是想把它放在一個脈絡裡看。依你看,我們是否正處在一個分界點,這會成為公司的一段定義性時期?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Well, Rich, it's always really -- it's hard to always call -- you're asking about the tipping point. And John has a great saying, you never know the tipping point until it's there, right? So but I would tell you that, obviously, in the current environment that we have right now where infection is a concern, digital becomes predominant in that sense of doctors looking at it.

    嗯,Rich,這一直都很——要去判斷——你問的是臨界點。John 有句很棒的話:你永遠不知道臨界點,直到它真的出現,對吧?不過我會說,顯然在我們目前所處的環境中,感染是一個顧慮,因此從醫師的角度來看,數位在這個意義上就變得更為主導。

  • But I think another good signal that you can say that this can become more permanent is what's really unusual here is take a look at iTero growing 25%, right? You see capital goods in a situation like this are going to lag because doctors aren't going to make that kind of a capital outlay when their businesses are under pressure. And what we saw in this case is iTero grew phenomenally.

    但我認為另一個可以說明這可能更具永久性的良好訊號是:真正不尋常的是,看看 iTero 成長了 25%,對吧?在這種情況下,資本設備通常會落後,因為當醫師的業務承受壓力時,他們不會做那樣的資本支出。而我們在這個案例中看到的是 iTero 的成長非常驚人。

  • And what we know, and you see that 93% of the cases in the United States right now for orthos are coming through digitally is, when you get an iTero scanner into an office, whether it's a GP or ortho, they've become really committed on the digital piece and want to learn.

    而我們知道——你也看到目前在美國,矯正科的病例有 93% 是以數位方式進來的——當你把一台 iTero 掃描儀放進診所,不論是一般牙醫(GP)或矯正科,他們就會在數位這一塊變得非常投入,並且想要學習。

  • So I think that kind of demand for iTero scanner, and what I call a hurricane right now from a doctor's cash flow standpoint, really shows that they're interested in the sense of this digital transformation and want to stick with it.

    所以我認為,對 iTero 掃描儀的那種需求,以及我所說的、目前從醫師現金流角度看像是一場颶風的情況,確實顯示他們對這種數位轉型有興趣,並且想要持續走下去。

  • Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst

    Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst

  • That's helpful. And maybe just one follow up on the competitive commencing question from the prior. I was just curious, your ability to train virtually and remotely and your customer base and your advantage together, are your competitors able to kind of get into the channel even as effectively as they might have otherwise been? Or are you basically kind of converting on your own right now?

    這很有幫助。再追問一個,關於前面那個競爭開始的問題。我只是好奇,你們能夠以虛擬與遠端方式訓練,加上你們的客戶基礎與優勢結合起來,你們的競爭對手是否也能像原本那樣有效地進入通路?還是說你們現在基本上是在自己完成轉換?

  • I'm just curious if there's just an inherent structural advantage that you have there during this period, and if competitor sales reps are allowed to engage as actively as you are.

    我想知道在這段期間,你們是否因此具備某種內在的結構性優勢,以及競爭對手的業務代表是否被允許像你們一樣積極地與客戶互動。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. It's -- forgive me if I don't answer your question properly, but what I derive from that is the importance of a sales force versus competition and the importance of training. And there's no company in the world that can provide digital training, whether it's virtual or if it's allowed in the future, which it will be obviously face-to-face across a number of platforms that Align can provide.

    是的。——如果我沒有正確回答你的問題,請見諒;但我從你的問題中理解到的是:銷售團隊相對於競爭的重要性,以及訓練的重要性。世界上沒有任何一家公司能像 Align 一樣,提供數位訓練——不論是虛擬的,或是未來(顯然會被允許的)面對面的——而且能跨越多種平台來提供。

  • ADAPT is another kind of training. ADAPT is Align digital and practice transformation program, that kind of -- there are experts that we put in place that understand doctors' office workflow and economics and how we can work through them. Our sales force is -- since I've been in this business 5 years now, and I've run sales forces and businesses pretty much my entire adult life, I have never seen such a high-touch sales force in my life. The importance of touch with the sales team with those doctors is incredibly important because of how different digital is from a workflow standpoint and a clinical standpoint than what an analog procedure is. So there's no way around that.

    ADAPT 是另一種訓練。ADAPT 是 Align 的數位與診所轉型計畫——我們配置的專家了解診所的工作流程與經濟模型,以及我們如何與他們一起推進。我們的銷售團隊——我在這個產業已經 5 年了,而我幾乎整個成年人生都在帶領銷售團隊與經營事業——我從未見過如此高接觸(high-touch)的銷售團隊。銷售團隊與醫師之間的接觸重要性極高,因為從工作流程與臨床角度來看,數位與類比流程差異非常大。所以這一點無可取代。

  • And then the last part is, maybe we're taking advantage of our competitors or something. And I don't say this in any arrogance or whatever, the competition's competition. I actually welcome it to a certain extent because it helps legitimize the digital space. Our job broadly is how do we go and get dentists and orthodontists to move from analog to digital, not so much what the next competitor's product is out there and that we're fighting for that extra ounce of share. That's not where we are right now. This is about an expansive marketplace.

    最後一部分是,你在問我們是否在某種程度上利用了競爭對手之類的。我不是以任何傲慢的態度在說,競爭就是競爭。我其實在某種程度上歡迎競爭,因為它有助於讓數位領域更具正當性。我們更廣泛的工作是:如何讓牙醫與矯正醫師從類比轉向數位;而不是太在意下一個競爭對手的產品是什麼,或我們為了多那一點點市占去打仗。我們現在不在那個階段。這關乎的是一個擴張中的市場。

  • Operator

    Operator

  • Our next question comes from the line of Ravi Misra with Berenberg Capital Markets.

    我們的下一個問題來自 Berenberg Capital Markets 的 Ravi Misra。

  • Ravi Misra - Analyst

    Ravi Misra - Analyst

  • Hope everyone's well. Just a -- to take a pivot to the GA for a second. And remembering correctly, prior versions of the systems have been seen as these step function advancements that have opened the door to more cases and more comfort with doing the system. But G8, just curious in terms of, number one, how do you see it kind of increasing the addressable market for the number of cases you can treat? I mean is this opening up doors that couldn't be done before by the sort of average dentist?

    希望大家都安好。我想稍微轉到 GA 談一下。回想一下,先前版本的系統常被視為階梯式的重大進步,能夠打開更多病例、也讓大家更有信心使用該系統。但對於 G8,我有兩個問題:第一,你們如何看待它提升可服務市場(addressable market),也就是可治療病例數的能力?我的意思是,這是否為一般牙醫打開了以前做不到的門?

  • And number two, do we have any sort of IP protection around this? I mean looking at the press release, it seems like a pretty powerful set of innovations and the way you're staging it? Or is this kind of a function or a development on top of existing technologies in that sense from an IP perspective?

    第二,我們是否對此有任何智慧財產權(IP)保護?從新聞稿來看,這似乎是一套相當強大的創新,以及你們分階段推出的方式。從 IP 的角度看,這是建立在既有技術之上的功能/開發延伸,還是有更明確可保護的部分?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. Ravi, good question. First of all, when you think of how we got the G8 is we've done 9 million patients, right? And probably deep bite cases are 30% of those cases and G8 is around deep bite. And when you do deep bite, there's a lot of extrusion in deep bite. Now I want to get too clinically into this thing, but extrusion just means you're pulling the tooth down or pushing a tooth up. And those are the most difficult movements that we make. They are the hardest movements to do.

    是的。Ravi,問得好。首先,談到我們如何做到 G8:我們已經治療了 900 萬名患者,對吧?而深咬(deep bite)病例大概占其中 30%,G8 就是圍繞深咬而設計的。做深咬時,會有很多「擠出」(extrusion)。我不想把臨床細節講得太深,但擠出指的是把牙齒往下拉或把牙齒往上推。這些是我們所做的最困難的移動之一,也是最難達成的移動。

  • When you talk about IP, it has to be with the specific kind of attachment. It's where you place that attachment. It's that interface of that attachment with the aligner and how the aligner -- actually, that's what we call it the activated part of this thing. And I'd say, do we have IP around that? Sure, we do. Do we have IP around doing a deep bite case? No. But our products are specifically geared to be able to do that.

    談到 IP,它必須與特定類型的附件(attachment)有關:你把附件放在哪裡、該附件與牙套之間的介面,以及牙套如何——其實這就是我們所說的這個系統的「啟動」(activated)部分。我會說,我們對此有 IP 嗎?當然有。我們對「做深咬病例」本身有 IP 嗎?沒有。但我們的產品是專門設計來能夠做到這件事的。

  • And so we use a lot of AI and machine learning to mine that database to figure out where these deep bite cases weren't finishing as fast as they could be at times. And the new G8 is supposed to make this better. It's been tried in different areas. And in the end, what it does, it gives doctors more confidence to be able to get into those cases and know they can finish in the way they want to finish. And that's the purpose of the product.

    因此,我們運用大量的 AI 與機器學習去挖掘那個資料庫,以找出這些深咬案例在某些時候未能以其本可達到的速度完成的原因。而新的 G8 應該能改善這一點。它已在不同地區進行過嘗試。最終,它所做的是讓醫師更有信心去接手這些案例,並知道他們能以自己想要的方式完成治療。這就是這項產品的目的。

  • Ravi Misra - Analyst

    Ravi Misra - Analyst

  • Great. And then maybe if I can build on that. So prepandemic, you guys were on a kind of case growth basis, somewhere in the 30s, high 20s range. I appreciate that it's very difficult to look past what's going on in the world right now. But today, we do kind of normalize at some point in the future postpandemic. With these innovations and the sales force touch points that you mentioned, is that 20% to 30% are kind of reasonable proxy for where this market can go?

    很好。那麼也許我可以在此基礎上再追問一下。疫情前,你們的病例成長大致在 30% 左右、或高 20% 的區間。我理解要看穿當前世界正在發生的事情非常困難。但從今天來看,未來某個時間點在疫情後終將回歸常態。結合你提到的這些創新以及銷售團隊的觸點,20% 到 30% 是否可作為這個市場可能走向的合理代理指標?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Ravi, this is John. Good question. When we think about the investments that we make in the -- as we've described, the vastly underpenetrated market that we're in, we look at our investments to say, look, we can grow revenue in the 20% to 30%. And that's how we think of things, and that's what we think that we can control, the investments that we're making to be able to grow in this market to that. We didn't guide to that because there's unknowns outside of what we can control and we've kept it at that.

    Ravi,我是 John。好問題。當我們思考在——如我們所描述的——我們所處這個滲透率極低的市場中所做的投資時,我們看待投資的方式是:我們可以讓營收成長在 20% 到 30% 的區間。這就是我們思考事情的方式,也是我們認為自己能掌控的部分——也就是我們所做的投資,以便在這個市場中達到那樣的成長。我們沒有對此給出指引,因為在我們可控範圍之外仍有未知因素,所以我們就維持在那樣的表述。

  • But certainly, when we look at investments in this market and the opportunities that we have, we look at those investments with the long-term growth model from a revenue standpoint of 20% to 30%.

    但可以肯定的是,當我們看待在這個市場的投資與我們所擁有的機會時,從營收角度來看,我們以 20% 到 30% 的長期成長模型來衡量這些投資。

  • Operator

    Operator

  • Our next question comes from the line of Michael Ryskin with Bank of America.

    下一個問題來自美國銀行(Bank of America)的 Michael Ryskin。

  • Michael Leonidovich Ryskin - Associate

    Michael Leonidovich Ryskin - Associate

  • I realized it's late, so I'll just keep it to one. Obviously, you see the strong -- really strong utilization numbers in the Americas for the orthos and GPs. But obviously, that's only half of the equation because you also got the number of docs actually receiving those.

    我知道時間有點晚了,所以我就只問一個。很明顯,你們在美洲地區的矯正科與一般牙科(GP)的使用率數據非常——真的非常強勁。但顯然這只是一半,因為你們還有實際收到這些產品的醫師數量。

  • So I was just wondering if you could provide any additional color on the split between ortho and GP, which really drove the volume in the quarter in the Americas. And what I'm getting at is, with the rebound you commented on from that pent-up demand, was there one part of your customer base that really accelerated better than the others? Or was it pretty broad-based?

    所以我想請問,你們能否就美洲地區本季的量主要由矯正科還是一般牙科所帶動,提供更多說明?我想問的是,針對你們提到的那波由被壓抑需求帶來的反彈,你們的客戶群中是否有某一部分加速得比其他部分更明顯?還是其實相當全面?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. I can take that, Michael. This is John. Really, when we look at the utilization and the growth that we saw was very broad. It was across GP and ortho. It was across multiple tiers. We just saw a good adoption of our technology as these practices opened. Patients ask for it by name, doctors use our product. There are many doctors that were higher up on the tiers, accelerated their cases. And then even new doctors or doctors that are at lower tiers, were able to increase the utilization.

    是的,Michael,我可以回答。我是 John。其實,當我們看使用率與我們看到的成長時,表現非常全面,涵蓋一般牙科與矯正科,也涵蓋多個層級。隨著這些診所重新開放,我們看到對我們技術的良好採用。病患會指名要求,醫師也會使用我們的產品。有許多在較高層級的醫師加速了他們的病例量。甚至是新醫師或在較低層級的醫師,也能提高使用率。

  • So we're very happy with the results that we saw from newer doctors to more experienced doctors and felt really good about how they were in that recovery mode. As we said, it's tough to understand and break out the piece of how much is pent-up demand versus run rate. But as we went through the quarter, as we said, we got stronger and stronger. So we feel good about the situation that we left Q3 with.

    因此,從新進醫師到更有經驗的醫師,我們對所看到的結果都非常滿意,也對他們處於復甦模式時的表現感到很不錯。正如我們所說,很難理解並拆分其中有多少是被壓抑需求、多少是常態運行水準。但在整個季度中,正如我們所說,我們的表現愈來愈強。因此,我們對 Q3 結束時的狀況感到樂觀。

  • Operator

    Operator

  • Our next question comes from the line of Jason Badner with Piper Sandler.

    下一個問題來自 Piper Sandler 的 Jason Badner。

  • Unidentified Analyst

    Unidentified Analyst

  • Great. This is [Guzman] here. Congrats on a nice quarter, everyone. Have a clarification question just real quick and then another I'll ask upfront here. Just that enhanced momentum building comment that you made for October, Joe, can you just confirm that, that holds for all major reporting channels you have with GPs and orthodontists?

    很好。我是 [Guzman]。恭喜各位本季表現不錯。我先快速釐清一個問題,然後再先把另一個問題一併提出。Joe,你在談到 10 月時提到動能持續增強的評論,你能否確認這適用於你們所有主要的回報渠道,包括一般牙科與矯正科?

  • And then I know it's early days for iGo Plus, but curious if you could just talk about initial feedback on the system in the first markets you entered in Europe, any learnings you can draw on the early days of that launch before you look to take that system into additional markets?

    另外,我知道 iGo Plus 還在很早期,但想請你談談該系統在歐洲首批進入市場的初期回饋,以及在你們準備把該系統推向更多市場之前,從這次早期上市中是否有任何可汲取的經驗?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes, Jason. First of all, I can confirm that it's across all channels, all markets. There's nothing really that I can cite that's -- it's not with that momentum that we -- on iPro Plus. iPro Plus is about just enhancing the ability of doctors that are on iPro to be able to do more enhanced cases. And the feedback is great.

    是的,Jason。首先我可以確認,這涵蓋所有渠道、所有市場。沒有什麼我可以特別指出說——我們在 iPro Plus 上沒有那樣的動能。iPro Plus 的重點在於提升使用 iPro 的醫師處理更進階病例的能力。而回饋非常好。

  • We started in Europe because that's where iPro really started from in a big way. And those are the first doctors that really asked for that. And then as -- and we've rolled that out in general. And it's really on the back of like the ClinCheck 6.0, the cloud-type-based product that we've done. It's one of the great things about digital platforms is you can expand them to be able to fit specifically in different markets at different times. And that's what iPro Plus really represents. So I hope that helps, Jason.

    我們從歐洲開始,因為 iPro 在那裡是以很大的規模起步的。那裡也是最早真正提出需求的醫師。接著——我們也已經整體推廣。這其實是建立在我們推出的 ClinCheck 6.0、雲端類型的產品之上。數位平台的一大優點是,你可以在不同時間把它們擴展,以便更貼合不同市場的需求。而 iPro Plus 正是這樣的代表。希望這能幫到你,Jason。

  • Operator

    Operator

  • There are no other questions in the queue. I'd like to hand it back to management.

    目前佇列中沒有其他問題。我想把時間交回給管理層。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Thanks, everyone. We appreciate your time today. If you have any follow-up questions, please contact Investor Relations, and we look forward to speaking to you at our Investor Day, November 23. Have a great night.

    謝謝各位。我們感謝大家今天撥冗參與。如果你有任何後續問題,請聯繫投資人關係部門(Investor Relations),我們也期待在 11 月 23 日的投資人日(Investor Day)與各位交流。祝各位晚安。

  • Operator

    Operator

  • Ladies and gentlemen, this does conclude today's teleconference. Thank you for your participation. You may disconnect your lines at this time and have a wonderful day.

    各位女士、先生,今天的電話會議到此結束。感謝各位的參與。此時您可以掛斷電話線,祝您有美好的一天。